OTC26-02-10p1.qxd 24/2/10 09:19 Page 1

26 February 2010

COMPANY NEWS 2 Merck & Co goes to rival Pfizer enjoys sales boost 2 from Wyeth Boehringer to buy the rest 3 of Japanese SSP business for consumer health chief Benckiser targets 4 Latin America and brands erck & Co has signalled its ambitions for leveraging Merck & Co’s consumer prod- Sanofi-Aventis’ Allegra may 5 Mfor its recently-acquired Consumer ucts brands to “capitalise on new growth oppor- switch in US by early 2011 division by appointing as the tunities, including expanding the consumer busi- GSK Consumer claims 6 operation’s head the leader of one of John- ness in markets outside of the US”. spectacular results son & Johnson’s multi-billion dollar global Heller takes charge of a portfolio of brands Merck & Co reports first 7 business units. covering the OTC, suncare and footcare cate- Consumer Health results Bridgette Heller,president of Johnson & gories. As well as the Claritin allergy and Mira- Oxford Nutrascience offers 8 Johnson’s global Baby business unit, will lead LAX laxative OTC brands, she will be respon- better taste Merck’s Consumer Health Care division – gain- sible for Coppertone suncare products and the GNC to form Chinese joint venture 9 ed when it acquired Schering-Plough last Nov- Dr Scholl’s footcare line. In 2009, Consumer Pharmstandard benefits as 10 ember – with a brief to grow the business in Health Care’s proforma sales in the US and leading brands grow non-US markets. Canada were US$1.28 billion. OTC Claritin SSL delays total control of BLBV 11 Heller,48, will succeed Stanley Barshay on alone contributed turnover of US$406 million 1 March. Barshay,former chairman of Scher- (see page 7). GENERAL NEWS 12 ing-Plough Consumer Health Care, postponed his retirement to lead the Consumer Health Care Creative research and development New Zealand could switch 12 division during the post-merger transition (OTC “With its focus on the consumer health care calcipotriol bulletin,16 September 2009, page 1). sector,” Heller said, “this is an exciting time to Perrigo wins patent case 13 As executive vice-president and president, join the new Merck.”She would pursue growth, over Reckitt’s Mucinex Consumer Health Care, Heller will report dir- she maintained, through enhanced innovation, MARKETING NEWS 15 ectly to Merck’s chairman, president and chief creative research and development, and impro- executive officer Richard Clark. Heller will also ved products. Mix-ups make Novartis 15 serve on the firm’s executive committee. Heller had served as president of Johnson rename Maalox variant “Consumer Health Care represents an attrac- & Johnson’s global Baby business unit since Bayer gets intimate with 18 tive growth opportunity for Merck,”Clark said, 2007. Prior to that, she had been global pres- German Canesten range noting that Heller would be leading growth ini- ident of Johnson & Johnson’s Baby,Kids and tiatives for Merck’s consumer business using Wound Care operations. FEATURES 20 her “impressive track record of leading multi- Before joining Johnson & Johnson in 2005, European licensing come 20 billion dollar businesses as well as exceptional Heller was managing partner of Heller Asso- under scrutiny marketing acumen”. ciates – which she founded – where she pro- vided “consumer-centric growth strategies” REGULARS Led global business at Johnson & Johnson for companies outside of the traditional con- While at Johnson & Johnson, he pointed out, sumer packaged-goods arena. Pharmacy viewpoint 16 she had led a global team across all functions Heller has also been general manager of – Alli ascends as Flomax arrives of a business unit that had worldwide revenues the Coffee Division of Kraft Foods as well as Events – Our regular listing 19 of over US$2.5 billion (C1.8 billion). chairman and chief executive officer of Chung’s People – Latest moves 22 Heller would be responsible, Clark added, ■ Continued on page 11 OTC26-02-10p2-3.qxd 23/2/10 12:56 Page 2

OTC COMPANY NEWS

Fourth-Quarter/Annual Results Pfizer enjoys sales boost from Wyeth

fizer said the Consumer Healthcare business Business Fourth-quarter sales Change Proportion Pit gained by acquiring Wyeth on 15 Octo- (US$ millions) 2008/2009 (%) of sales (%) ber had contributed sales of US$494 million (C363 million) to the company’s new Diversi- Animal Health 901 +15 5.4 fied businesses division in the period between Consumer Healthcare494 –3.0 completion and the end of 2009. Capsugel 223 +10 1.3 The Consumer Healthcare business – which Nutrition 191 –1.2 includes the Advil, Centrum and Robitussin Diversified 1,809 +83 10.9 brands – accounted for 27% of the division’s Biopharmaceutical 14,606 +30 88.3 total sales in the fourth quarter of 2009, which Other 122 +3 0.7 increased by 83% to US$1.81 billion (see Fig- ure 1). Pfizer’s existing brands only contribut- Total Pfizer 16,537 +34 100

ed 1 percentage point to the division’s growth, Figure 1: Breakdown of Pfizer’s fourth-quarter sales in 2009 by business. Sales include contributions from with Wyeth accounting for 77 percentage points. former Wyeth businesses from 15 October 2009 (Source – Pfizer) A favourable foreign exchange effect added another 5 percentage points. of the Consumer Healthcare business to allocate Pfizer’s total group sales for the fourth quar- Animal Health contributed half of the divi- capital appropriately and encourage growth. ter of 2009 increased by 34% to US$16.5 bil- sion’s sales, while the Capsugel capsule busi- Pfizer has just added to Consumer Health- lion. The majority of the growth came from the ness generated a further 12%. The Nutrition care’s management team by appointing Todd Wyeth acquisition, with a favourable currency operation accounted for the remaining 11%. Magazine as president for the US and Canada effect adding a further 4%. The Diversified In October last year,Jeffrey Kindler,Pfizer’s and Mark Gelbert as senior vice-president for businesses division accounted for 11% of the chairman and chief executive officer,stressed global research and development (see page 22). total group sales in the quarter. that the Consumer Healthcare business would Acquiring Wyeth for US$68 billion has Over the full year,Pfizer said its sales had not be sold like its predecessor (OTC bulletin, broadened Pfizer’s portfolio and returned the increased by 4% to US$50 billion. Wyeth con- 30 October 2009, page 3). company to the consumer healthcare market tributed US$3.3 billion – or 7% – of the growth, Although Kindler refused to go into specifics just three years after it sold its own global OTC while Pfizer’s existing products contributed about how the business would be developed, business to Johnson & Johnson (OTC bulletin, US$247 million or 1%. This was offset by a neg- he said it was incumbent on Pfizer and leaders 25 January 2007, page 6). ative 4% currency effect. OTC

Retailing of the DocMorris Apotek chain in Sweden. The Swedish market, with one pharmacy for DocMorris pharmacy opens in Sweden around 10,700 inhabitants,was highly attractive, Celesio pointed out, noting that in Germany, elesio’s DocMorris Apotek has become the 10 in a city that had 100,000 residents, Cele- there was one pharmacy for every 3,800 people. Cfirst entirely new pharmacy brand to start sio pointed out. In November of last year,Sweden’s gov- operating in Sweden since the market was lib- Celesio announced plans to enter the Swe- ernment sold-off 615 of the 945 pharmacies eralised in 2009. It has opened the first phar- dish pharmacy market in July last year (OTC that had been under state-control as part of the macy in what it expects will become a chain of bulletin,31 July 2009, page 3). The company Apoteket chain (OTC bulletin,16 November more than 100 across Sweden. decided against buying any of the state-owned 2009, page 1). Noting that Sweden was the third country in Apoteket pharmacies the Swedish government The government sold 465 pharmacies to four which the DocMorris brand had a presence – put up for sale when it liberalised the country’s Nordic buyers – including Finland’s Oriola-KD after Germany and Ireland – the pan-European pharmacy market, and instead said it would ent- – for a total of SEK5.9 billion (C0.6 billion). A wholesaler and retailer said the new store also er the market by establishing its own entirely further 150 pharmacies were made available to marked the latest stage in the brand’s interna- new chain under the DocMorris name (OTC small businesses, while 330 pharmacies remain tional expansion. bulletin,30 September 2009, page 3). under the control of Apoteket. Fritz Oesterle – chief executive officer of Explaining the decision, Celesio said the plan The opening of the new Swedish pharmacy Celesio – said that customers of DocMorris required the “least initial capital” for entry. The came shortly after Oesterle said Celesio was Apotek could expect “better service, profes- DocMorris Apotek chain in Sweden would be considering the future of its pharmacy opera- sional advice, longer opening hours and com- developed “step-by-step”, with 20-30 pharma- tions in Ireland, Italy and the Netherlands (OTC petitive prices”. Celesio was “convinced”, he cies opening each year,the company noted, with bulletin,20 January 2010, page 6). Celesio twice added, that its “full-service pharmacy concept a medium-term goal of opening 100 stores. cut the goodwill valuations of its pharmacy op- of DocMorris Apotek” would be successful. Celesio’s Norwegian subsidiary Norsk Med- erations in the three countries by over C200 mil- DocMorris Apotek’s first pharmacy is based isinaldepot (NMD), which operates the Vitus- lion during 2009 (OTC bulletin,16 October in the city of Eskilstuna, 100 kilometres west apotek pharmacy chain and wholesaling busi- 2009, page 1). of Stockholm. The pharmacy was one of only ness in Norway,will be leading the development OTC

2 OTC bulletin 26 February 2010 OTC26-02-10p2-3.qxd 23/2/10 12:56 Page 3

COMPANY NEWS OTC

Mergers & Acquisitions Retailing/Annual Results Boehringer to buy the rest Oriola-KD ready of Japanese SSP business to go in Sweden riola-KD’s first Swedish pharmacies will oehringer Ingelheim is set to buy the 40% Andreas Barner,chairman of Boehringer In- Obe open before the end of February,ac- Bstake in its Japanese consumer healthcare gelheim’s board of managing directors, said the cording to the Finnish firm’s president and chief subsidiary,SSP,that it does not already own. deal would allow the German pharmaceutical executive office Eero Hautaniemi. The German firm, which has held a majority group to “enhance its global Consumer Health The wholesaler and retailer teamed up with stake in SSP since 2001 (OTC bulletin,16 Nov- Care business by sharing SSP’s knowledge”. Scandinavian retail group Kooperativa Förbun- ember 2001, page 1), expects to pay up to ¥33 “SSP’s research and development – with unique det(KF) to acquire 171 of the 615 former state- billion (C270 million) for the outstanding shares. pharmaceutical development and production owned Apoteket pharmacies that the Swedish SSP generates annual sales of around ¥48 bil- technologies – is expected to play an important government put up for sale last year when it lib- lion from a portfolio of brands including the S- role within the Boehringer Ingelheim group,” eralised the country’s pharmacy market (OTC Cup tonic drinks, S-Tac cough and cold medi- added Barner. bulletin,16 November 2009, page 1). cines, and Hythiol-C vitamin C products. SSP,meanwhile, would benefit from Boeh- Speaking as Oriola-KD announced its an- ringer Ingelheim’s new product development nual results for 2009, Hautaniemi said that expertise. The German company pointed out after “careful preparations” the company was that the cold medicine S-tac-eve-fine, which had now ready to start pharmacy operations in Swe- OTC bulletin been developed from the ingredient ambroxol den. The company’s first pharmacies will open owned by Boehringer Ingelheim, had been a in Malmö and Stockholm. 26 February 2010 Number 337 successful OTC switch in Japan. Oriola-KD’s Swedish pharmacy chain will The two companies would also benefit from operate through a joint venture with KF called Editor & Publisher: Deborah Wilkes shared corporate resources, added Boehringer Kronans Droghandel Retail. The joint venture Associate Editors: Aidan Fry Ingelheim, as well as cost reductions through firm – in which Oriola-KD holds an 80% stake Mike Rice joint procurement of raw materials. – is paying the Swedish government around Senior Assistant Editor: Matt Stewart Boehringer Ingelheim’s Consumer Health SEK1.56 billion (C162 million) for the 171 Assistant Editor: Jenna Lawrence Care business achieved sales up by 4.3% to pharmacies, which had proforma net sales of Advertising Controller: Debi Minal C1.19 billion in 2008. It accounted for 10.3% of SEK4.4 billion in 2008 and held a 14.5% share Marketing Manager: Val Davis group sales up by 5.9% to C11.6 billion (OTC of the Swedish pharmacy market. bulletin,30 April 2009, page 10). Oriola-KD will be responsible for develop- Editorial, Subscription and Advertising enquiries should be addressed to: OTC bulletin, The Asia, Australasia, Africa region, includ- ing and managing the pharmacy chain, while OTC Publications Ltd, 54 Creynolds Lane, Solihull, ing Japan, accounted for 31% of turnover by KF will open new pharmacies in conjunction West Midlands B90 4ER, UK. Boehringer Ingelheim’s Consumer Health Care with its Coop hypermarkets and supermarkets. Tel: +44 1564 777550. Fax: +44 1564 777524. business in 2008. In November 2009, the company said estab- E-mail: [email protected]. The tender offer has been issued through lishing a Swedish pharmacy chain fitted its Subscriptions Boehringer Ingelheim Japan Investment (BIJI), strategy of expanding operations from pharma- Annual subscriptions to OTC bulletin in Europe are £595.00 for single copies and £345.00 for additional copies to the same ad- a Japanese company set up by Boehringer In- ceutical wholesale to pharmaceutical retail in dress, including delivery. Subscriptions to addresses outside Eur- gelheim for this purpose. all countries where it operated and where mar- ope are subject to an additional charge of £30.00 to cover postage. Subscription enquiries in Korea should be directed to Pharma SSP’s board of directors has recommended ket regulations permitted. Koreana Ltd, 14th Floor,KTB Network Building, 826-14 Yeoksam- the offer to shareholders. Meanwhile, Oriola-KD said its sales had dong, Kangnam-gu, Seoul 135-080, Korea (Tel: +82 2 554 9591; Fax: +82 2 563 8289; E-mail: [email protected]). Once the transaction is completed, SSP will improved by 8% to C1.71 billion in 2009, while Advertising be part of Boehringer Ingelheim’s Consumer its operating profit had grown 10-times faster, Advertising rates and data are available on request from the ad- Health Care business. finishing up by 80% to C65.4 million. Growth dress above or at www.otc-bulletin.com. OTC About OTC bulletin in Russia,coupled with investments and im- OTC bulletin is published 20 times a year by OTC Publications proved efficiencies had driven the results. Limited: twice monthly in February,March, April, May,June, Sep- tember,October and November; and monthly in December,Jan- The company entered the Russian market uary,July and August. A subscription to OTC bulletin includes IN BRIEF in 2008 by acquiring a 75% stake in retailer the weekly electronic newsflash, news@OTCbulletin,which is published around 45 times a year. OTC bulletin is printed by the ■ MERZ PHARMA GROUP – owner of the Vitim & Co and wholesaler Moron for be- Warwick Printing Company Limited, Caswell Road, Leamington Tetesept cough and cold brand – has success- tween C70 million and C90 million (OTC bul- Spa CV31 1QD, UK. No part of this publication may be copied, reproduced, stored fully completed its tender offer for the med- letin,31 March 2008, page 1). in a retrieval system or transmitted in any form without prior ical aesthetics company BioForm Medical. At the time, Oriola-KD said the acquisition permission from OTCPublications Ltd. The German firm announced in January that it would provide the company with the “know- ©OTC Publications Ltd. All rights reserved. Company registered in England No 2765878. Registered Office: would pay around US$253 million (C 187 mil- ledge and know-how” to run a pharmacy chain 54 Creynolds Lane, Solihull, West Midlands B90 4ER, UK. lion) for BioForm, which it said was a leader and an integrated retail and wholesale opera- OTC bulletin® is registered as a trademark in the European in the dermal filler market in the US and Eur- tion as well as aid the creation of an integrated Community. ope (OTC bulletin,20 January 2010, page 6). business model in Sweden. ISSN 1350–1097 www.OTC-bulletin.com OTC OTC

26 February 2010 OTC bulletin 3 OTC26-02-10p4-5.qxd 23/2/10 12:57 Page 2

OTC COMPANY NEWS

Annual Results Reckitt Benckiser targets Latin America and brands

aining infrastructure in the Latin American sonal Care business rose by 14% at constant Ghealthcare market and adding more power- exchange rates to £2.08 billion in 2009. The brands to the Health & Personal Care business actual rise was higher at 24% (see Figure 1). are high on the agenda for Reckitt Benckiser, Becht said the business had posted “very according to chief executive officer . good growth”, driven by its Healthcare power- Reporting Reckitt Benckiser’s 2009 results, brands Gaviscon, Nurofen and and the

Becht said the UK-based company was also Personal Care powerbrand . Reckitt Benckiser is expanding its line with keen to achieve critical mass in East Asia. The company’s strategy of rolling out its the Clearasil Overnight range which it claims “visibly The chief financial officer Colin Day add- Health & Personal Care powerbrands into new reduces redness and spots whilst sleeping” ed that strategic acquisitions were likely to in- markets had continued during 2009, added volve emerging markets and, from a product Becht, noting that the core Nurofen range – keting investment had produced an “excellent category point of view, would in all likelihood including standard tablets and liquid capsules result” for the Dettol personal-care range in be made in the health and personal care seg- – had been relaunched in Greece and Spain developing markets, added the company, not- ment of the business. during the year,while Strepsils had been intro- ing that Gaviscon and had also both con- Day also stressed that the firm was not aim- duced into Egypt, Indonesia,Malaysia and tributed strongly. ing to become “a big pharma player” by invest- Nigeria and had been relaunched in . The Looking ahead, Becht said that Reckitt Ben- ing in the prescription pharmaceutical space, roll-out of Gaviscon had also continued. ckiser aimed to introduce the Strepsils Handy which he described as “a very niche” area. Tube into other countries following an encour- Reckitt Benckiser’s most recent big health- 90% of growth in existing markets aging reaction to the new pack in the UK since care acquisition was the US$2.3 billion (C1.7 Becht pointed out, however, that more than its launch in November (OTC bulletin,16 Nov- billion) purchase of US-based Adams Respira- 90% of the growth achieved by its Healthcare ember 2009, page 17). Becht said the “com- toryTherapeutics and its Mucinex cough brand brands in the future was expected to be gener- pact and portable packaging” meant consum- at the start of 2008 (OTC bulletin,15 Febru- ated in existing markets where brand loyalty ers could, for the first time, take Strepsils with ary 2008, page 3). This followed the £1.90 bil- had been established over a number of years. them wherever they went. lion (C2.19 billion) acquisition of Boots Health- In addition to Gaviscon, Nurofen and Strep- Meanwhile, continued Becht, the Clearasil care International in 2006 (OTC bulletin,14 sils, the Healthcare business has the Mucinex range of skincare products would be expanded February 2006, page 3). powerbrand, while the Personal Care power- in all markets with the Clearasil Overnight A year ago, the company said it could spend brands include Clearasil and Veet as well as range of products, which “visibly reduce red- another £3 billion-£4 billion building its health- the Dettol range. ness and spots whilst sleeping”. The range com- care portfolio, but did not believe the opportu- Commenting on Health & Personal Care’s prises a wash, lotion and serum. nities were available (OTC bulletin,27 Febru- performance in the main geographic regions, This year will also see the arrival of the Ly- ary 2009, page 4). There was speculation to- Reckitt Benckiser said Gaviscon, Nurofen and sol No-Touch Hand Soap System, which is wards the end of 2009 that Reckitt Benckiser Strepsils had all performed strongly in Europe, designed to “remove the need to touch a grimy was about to announce a major deal (OTC bul- boosted by increased marketing investment; soap pump ever again”. A strapline on the pack- letin,30 November 2009, page 3). while Mucinex had driven growth in the North aging points out that the product “Helps stop Sales at Reckitt Benckiser’s Health & Per- America & region. Additional mar- the spread of bacteria”. A line of Veet Suprem’Essence hair-removal Business Annual sales Change 2008/2009 (%) products based on essential oils will also be (£ millions) £CER* launched during 2010. Health & Personal Care was the largest busi- Health & Personal Care2,078 +24 +14 ness for Reckitt Benckiser in 2009. It account- Fabric Care1,578 +7 ±0 ed for 26.8% of group sales up by 8% at con- Surface Care1,290 +16 +5 stant exchange rates – or by 18% at actual ex- Home Care1,036 +14 +4 change rates – to £7.75 billion. Dishwashing 843 +12 +2 Group operating profit grew by 14% at con- Other Household65-3-12 stant exchange rates – or by 26% at actual ex- Household and Health & Personal Care 6,890 +15 +6 change rates – to £1.89 billion in 2009. Pharmaceuticals 588 +72 +50 Group sales in the fourth quarter of 2009 Food 275 +22 +5 improved by 10% at constant exchange rates Total Reckitt Benckiser 7,753 +18 +8 to £2.06 billion,as Health & Personal Care sales grew by 13% at constant exchange rates * CER is constant exchange rates to £567 million. Figure 1: Reckitt Benckiser’s sales in 2009 broken down by business (Source – Reckitt Benckiser) OTC

4 OTC bulletin 26 February 2010 OTC26-02-10p4-5.qxd 23/2/10 12:57 Page 3

COMPANY NEWS OTC

Annual Results/Business Strategy Sanofi-Aventis’ Allegra may Doliprane 14.6% Essentiale 7.1%

switch in US by early 2011 No-spa 5.1%

Enterogermina 4.5%

anofi-Aventis’ allergy brand Allegra (fexo- lone), and the antifungal Penlac (ciclopirox). Maalox 4.5% Sfenadine hydrochloride) could be switched Commenting on the acquisition, Chris Vieh- Others Magné B6 4.1% 52.9% Dorflex 3.8% from prescription-to-OTC status in the US by bacher,chief executive officer of Sanofi-Aventis, Lactacyd 3.3% early 2011,according to Hanspeter Spek, pres- said that other companies had tried and failed to ident of global operations at the French pharma- acquire Chattem, but the potential to switch Al- Figure 3: Sanofi-Aventis’ Consumer Health Care ceutical company. legra had captured the US firm’s imagination. sales in 2009 – C 1.43 billion – broken down by brand (Source – Sanofi-Aventis) Spek said a switch submission would be filed Viehbacher noted that a successful switch in the US during the first quarter of 2010, and of Allegra could double Chattem’s sales. The creased by 22.1% during the year,and repre- Sanofi-Aventis was confident that Allegra would US-based company had annual sales of US$463 sented 47.1% of the company’s total Consumer be an OTC medicine by early 2011. million, he pointed out, adding that established Health Care sales (see Figure 3). Growth had The potential to switch Allegra in the US OTC allergy brands in the US, such as McNeil’s been driven primarily by the Doliprane and was the driving force behind Sanofi-Aventis Zyrtec and Schering-Plough’s Claritin, gener- Essentiale brands, the company added. agreeing to pay US$1.9 billion (C1.4 billion) to ated a similar figure on their own. Doliprane was the “number one selling acquire US firm Chattem at the end of last year Acquiring Chattem has also given Sanofi- in France”, commented Viehbach- (OTC bulletin,20 January 2010, page 1). The Aventis a direct presence in the US OTC mar- er,adding that it was also Sanofi-Aventis’ big- tender offer was completed on 10 February. ket for the first time, and created a global Con- gest-selling product by volume in the country Announcing the deal, Sanofi-Aventis said sumer Health Care business with proforma 2009 and would soon also be the company’s “num- Chattem would provide a strong vehicle for sales of around C1.77 billion. With Chattem on ber one selling product by value”. switching some of its medicines, including Alle- board, Sanofi-Aventis is now the fifth-largest Consolidating acquired businesses also help- gra, from prescription-to-OTC status. The com- consumer healthcare company in the world. ed drive up sales. Sanofi-Aventis acquired Sym- pany’s switch pipeline also includes the acne As can be seen from Figure 1, Chattem will bion Health’s consumer healthcare business in medicine BenzaClin (clindamycin/benzoyl per- contribute almost a fifth of Sanofi-Aventis’ Con- Australia and New Zealand in 2008 (OTC bul- oxide), the corticosteroid Nasacort (triamcino- sumer Health Care sales, and will mean the letin,31 July 2008, page 1), while Zentiva’s US is the company’s third-biggest geographic OTC activities came on board when the deal for

Eastern Europe region – in terms of Consumer Health Care sales the Czech generics company was completed 20% US (Chattem) – behind western Europe and eastern Europe. in March last year. 19% Excluding Chattem, Sanofi-Aventis’ Con- In 2009, the firm made OTC acquisitions in sumer Health Care sales in 2009 increased by Argentina with Gramon, the Netherlands with 18.9% to C1.43 billion (see Figure 2), thanks Kernpharm, and France with Oenobiol (OTC Latin America to organic growth of key brands coupled with bulletin,16 November 2009, page 1). 14% bolt-on acquisitions. At constant exchange rates, This year,Sanofi-Aventis has set up a joint growth was even faster at 26.8%. On a con- venture company with Minsheng Pharmaceu-

Asia Pacific stant-structure and exchange-rate basis, the im- tical Group to produce vitamin and mineral sup- Western Europe 9% 35% provement was still a strong 8.1%. plements for the Chinese OTC market (OTC Africa & Middle East 3% The French company said sales of its eight bulletin,10 February 2010, page 2). flagship Consumer Health Care brands – Doli- Figure 1: Sanofi-Aventis’ proforma Consumer Health Care sales in 2009 including Chattem in the US – prane, Dorflex, Essentiale, Enterogermina, Lact- Acquired Ostelin in Australia C1.77 billion – by region (Source – Sanofi-Aventis) acyd, Maalox,Magné B6 and No-Spa – had in- It has also just acquired the Ostelin vitamin D and calcium supplements in Australia from Business Annual sales Change 2008/2009 (%) Reckitt Benckiser for an undisclosed sum. (C millions) C CER* In the fourth quarter of 2009, Consumer Health Care sales at Sanofi-Aventis rose by Flagship prescription drugs 13,278 +6.4 +4.6 28.2% to C405 million. Growth was36.1% at Other prescription drugs 4,025 ––constant exchange rates, and 19.1% on a con- Other products 6,078 -6.3 -6.0 stant-structure and exchange-rate basis. Consumer Health Care1,430 +18.9 +26.8 Spek noted the company had started to re- Generics 1,012 +185.9 +198.0 structure and optimise its OTC product port- Pharmaceuticals 25,823 +4.5 +3.7 folio during the year and had reinforced its Vaccines 3,483 +21.7 +19.2 management team with Hans Regenauer,form- Total Sanofi-Aventis 29,306 +6.3 +5.3 er worldwide head of Boehringer Ingelheim’s Consumer Health Care business (OTC bul- * CER is constant exchange rates letin,20 January 2010, page 22). Figure 2: Sanofi-Aventis’ sales in 2009 broken down by business (Source – Sanofi-Aventis) OTC

26 February 2010 OTC bulletin 5 OTC26-02-10p6-7.qxd 24/2/10 09:21 Page 2

OTC COMPANY NEWS

Annual Results GSK Consumer claims spectacular results

laxoSmithKline’s Consumer Healthcare ment, with the exception of UK nutritionals,” But more spending held no advantage, Witty Gdivision posted “spectacular” results in Witty noted, “and in the US we increased our pointed out, if the advertisements were “rub- 2009, according to chief executive officer And- share of the oral care toothpaste market by over bish”. As many as 83% of Consumer Health- rew Witty,with worldwide sales growing by three percentage points.” care’s advertisements across all mediums rank- 7% at constant exchange rates to £4.65 billion Consumer Healthcare’s returns from its ed highly in external tests for persuasion and (C5.34 billion). spending on advertising and on innovation were brand recognition, he said. Witty pointed out that the growth at Con- increasing, Witty maintained, referring to two Meanwhile, Witty noted that spending on in- sumer Healthcare – which comprises OTC areas which had been key priorities for the divi- novation had increased two-fold since he took Medicines, Oral Care and Nutritional Health- sion over the past two years. charge of GlaxoSmithKline in May 2008 (OTC care businesses – had been achieved in a year Largely funded by cost savings,spending on bulletin,12 October 2007, page 4). This, he be- when most of the world’s economies had been advertising – excluding campaigns for Alli and lieved, was why Consumer Healthcare had been in recession and in a marketplace that had central nervous system brands – had grown in- able to keep some of its biggest brands so cur- grown by only 2%. crementally from less than £50 million in 2005 rent in a period of recession. “We grew market share in almost every seg- to nearly £200 million in 2009. Not all the spending, however, was financed by cost savings. Despite the sales improvement, Annual sales Change 2008/2009 (%) Proportion there was not parallel profit growth, as Con- (£ millions) £CER* of total (%) sumer Healthcare’s operating profit dropped by Sales 1% to £952 million at constant exchange rates. Pharmaceuticals 23,714 +16 +2 84 Explaining the discrepancy, Witty said that the company had needed to get the Consumer Consumer Healthcare 4,654 +17 +7 16 Healthcare division “to the right level of invest- Total 28,368 +16 +3 100 ment”, a process he said had continued through Operating profit the final quarter of 2009 and had been vindi- Pharmaceuticals 9,475 –-391cated by the “fantastic” January the division Consumer Healthcare 952 –-19had just experienced. Total** 8,425 +18 +4 100 Now the right level of investment had been achieved, Witty said, he fully expected to see * CER is at constant exchange rates ** Including corporate and restructuring costs of £2,002 million profit growth come alongside sales growth. Figure 2: GlaxoSmithKline’s sales and operating profit in 2009 (Source – GlaxoSmithKline) OTC Medicines generated half of Consum-

Business TOTALREST OF WORLD EUROPE NORTH AMERICA** Sales Change (%) Sales Change (%) Sales Change (%) Sales Change (%) (£mn) £CER* (£mn) £CER* (£mn) £CER* (£mn) £CER* Panadol franchise 393 +21 +10 294 +20 +8 99 +25 +18 ––– Smoking cessation339 +13 -1 28 +8 -4 64 +7 +5 247 +16 -2 Alli 203 >100 >100 2-50 -50 105 –– 96 +35 +14 Cold-sore franchise 96 +8 -3 12 +20 +10 38 ±0 -5 46 +12 -5 Tums 106 +16 -1 13 +8 -8 1±0±092+18 ±0 Breathe Right 92 +14 -1 20 +54 +38 22 +10 ±0 50 +4 -13 Others1,090 –– 480 –– 419 –– 191 –– Total OTC Medicines 2,319 +20 +8 849 +22 +9 748 +23 +18 722 +15 -3 Aquafresh franchise 496 +10 -1 112 +20 +5 291 +6 -2 93 +11 -6 Sensodyne franchise 457 +26 +13 158 +32 +17 195 +11 +4 104 +53 +29 Denture care336 +24 +8 134 +37 +15 125 +14 +5 77 +22 +3 Biotene 26 >100 >100 4–– 3–– 19 >100 >100 Others169 –– 17 –– 146 –– 6–– Total Oral Healthcare 1,484 +20 +7 425 +30 +13 760 +10 +2 299 +35 +14 Lucozade 376 -2 -3 53 +15 +11 323 -4 -5 ––– Horlicks 255 +25 +17 236 +30 +21 19 -14 -14 ––– Ribena 160 -1 -4 47 +18 +5 113 -7 -7 ––– Others60– –58– –2–– ––– Total Nutritional Healthcare 851 +7 +3 394 +25 +17 457 -5 -6 ––– Total Consumer Healthcare4,654 +17 +7 1,668 +24 +12 1,965 +10 +5 1,021 +20 +1

* CER is at constant exchange rates ** North America includes Canada, Mexico and the US

Figure 1: GlaxoSmithKline Consumer Healthcare’s sales in 2009 (Source – GlaxoSmithKline)

6 OTC bulletin 26 February 2010 OTC26-02-10p6-7.qxd 23/2/10 12:58 Page 3

COMPANY NEWS OTC

er Healthcare’s sales in 2009, growing by 8% Fourth-Quarter/Annual Results at constant exchange rates to £2.32 billion, mostly as a result of the European launch of Merck & Co reports first the OTC weight-loss medicine Alli. Alli was the third best-selling OTC brand in Europe during 2009, according to Witty,ach- ieving sales of £105 million in the nine months Consumer Health results after its launch in 24 countries across the Euro- pean Union in April 2009 (see Figure 1). erck & Co’s new Consumer Health Care – including Coppertone, Dr Scholl’s and Mira- By the end of the year,Alli was available to Mdivision generated sales of US$149 mil- LAX as well as Claritin – under the Merck buy in all 27 member states of the European lion (C 108 million) in the US and Canada for umbrella. The Consumer Health Care division Union plus Norway and . the period between 3 November 2009 – when is set to be extended further with the forthcom- Europe accounted for just over half of Alli’s the US-firm gained the business as part of its ing launch of the omeprazole-based heartburn worldwide sales in 2009, which more than dou- acquisition of Schering-Plough – and the end medicine Zegerid OTC in the US (OTC bul- bled at constant exchange rates to £203 mil- of the fourth quarter. letin,18 December 2009, page 14). lion. US sales grew by 14% at constant ex- International sales of Schering-Plough’s con- Prior to the acquisition, Merck had only an change rates to £96 million, with the Rest of sumer healthcare brands are now included in indirect presence in the OTC market through World region contributing the remainder. Merck & Co’s Human Health division results. the Johnson & Johnson/Merck Consumer Phar- Although Alli’s US sales experienced a Consumer Health Care’s sales were driven maceuticals joint venture. double-digit rise, the brand’s US turnover suf- by “solid demand” for the OTC Claritin allergy Responding to a question during the firm’s fered in the second half of the year. Sales were brand – which reported sales of US$39 million 2009 results press conference on plans for the static after the Food and Drug Administration’s (see Figure 1) for the post-merger period – and Consumer Health Care division, Richard Clark, (FDA’s) “early communication about an on- footcare products, according to Merck & Co. chairman, president and chief executive officer going safety review” into the brand’s active The results are the first from Merck & Co of Merck & Co, said Consumer Health Care ingredient orlistat (OTC bulletin,31 August since it completed its US$41 billion acquisi- would play an important part in building the 2009, page 1). In the final three months of tion of smaller rival Schering-Plough (OTC bul- company’s presence in emerging markets. 2009, the brand’s sales dropped by 18%. letin,17 March 2009, page 1). Schering-Plough had done an outstanding Away from Alli, Panadol – the OTC busi- Consumer Health Care is one of the “five job of building the business within the US, ness’ biggest-selling product – posted turn- primary divisions” in the enlarged company. Clark said, but added that Merck was putting over up by 10% to £393 million (see Figure 2). The others are Global Human Health – includ- together a strategy to use the Consumer Health In contrast, sales of smoking-cessation prod- ing prescription, vaccines and biologics busi- Care division to increase its presence in emerg- ucts dropped by 1% at constant exchange rates ness units – Animal Health, Merck Manufac- ing markets such as Brazil and . to £339 million, while the firm’s cold-sore fran- turing and Merck Research Laboratories. chise – which includes the Zovirax brand – slip- If Schering-Plough had been included for Heller to lead Consumer Health Care ped back by 3% to £96 million, also at constant the full fourth quarter,then Consumer Health Meanwhile, Merck & Co’s search for a per- exchange rates. Care’s sales would have stood at US$232 mil- manent head for its Consumer Health Care has lion, Merck & Co said. Consumer Health Care ended with the appointment of Bridgette Heller, Oral Healthcare sales grew by 7% accounted for 2% of the enlarged Merck & Co’s former president of Johnson & Johnson’s glo- Oral Healthcare sales moved forward by total proforma fourth-quarter sales which in- bal Baby business unit (see front page). 7% to £1.48 billion, led by the 13% growth creased by 7.0% to US$12.2 billion. Effective 1 March 2010, Heller will become of the Sensodyne brand. Sales of Aquafresh Meanwhile, full-year Consumer Health Care executive vice-president and president, Con- fell by 1% due to a decline in sales of pre- proforma sales stood at US$1.28 billion,with sumer Health Care, reporting to Clark. She re- mium whitening products in the US. OTC Claritin contributing US$406 million. places Stanley Barshay – previously chairman Horlicks rose by 17% driving the 3% in- Merck & Co’s total proforma 2009 sales of Schering-Plough Consumer Health Care – crease in Nutritional Healthcare turnover to slipped back by 1.7% to US$46.0 billion. who led the business during the transition (OTC £851 million on a constant exchange rate basis. Acquiring Schering-Plough bought a num- bulletin,16 September 2009, page 1). Lower sales in the “impulse” segment of the ber of established consumer healthcare brands OTC UK market led to sales of Lucozade dropping. Meanwhile, GlaxoSmithKline announced Business Fourth-quarter sales Change Proportion that it was expanding the Consumer Health- (US$ millions) 2008/2009 (%) of total (%) care division by adding a Dermatology unit Human Health* 9,072 +64 90 ( OTC bulletin,10 February 2010, page 1). The new unit would cover the acne, dry skin, Animal Health 494 –5 sun-protection and anti-ageing categories, ex- Claritin OTC39–0.4 plained the company, and would bring together Consumer Health Care** 149 –1 GlaxoSmithKline’s existing OTC dermatology Other 379 –4 brands with the consumer dermatology brands Total Merck & Co 10,093 +67 100 gained through acquiring Stiefel Laboratories in April of last year (OTC bulletin,30 April * Includes international Consumer Health Care sales ** US and Canada only

2009, page 1). Figure 1: Merck & Co’s sales in the fourth quarter of 2009 broken down by business. Figures include sales from OTC Schering-Plough acquired on 3 November 2009 (Source – Merck & Co)

26 February 2010 OTC bulletin 7 OTC26-02-10p8-9.qxd 23/2/10 12:59 Page 2

OTC COMPANY NEWS

Business Opportunities Oxford Nutrascience offers better taste

xford Nutrascience is seeking brand-own- bald and another ex-Boots man, Marcelo Bravo. Oers worldwide to license its delivery sys- Theobald was involved with OTC medicines tems that use prebiotic soluble fibres to make and healthcare product development at Boots, medicines and food supplements more pleas- while Bravo worked in new business develop- ant to take. ment for the company. Bravo also worked in Chief executive officer Nigel Theobald said research and development at Procter & Gamble. the company’s chewy confectionery,chewable Oxford Nutrascience has just raised £1.1 mil- tablets and liquid suspensions could “improve lion before expenses through an initial public taste, mouth feel and active ingredient dispers- offering on ’s Alternative Investment ability”. They could also add prebiotic health Market (AIM). The company now has cash re- benefits to products, he remarked. sources of approximately £1.5 million, which The UK-based company also wants to find it plans to use to “develop the business and business partners around the world for its Ell- fund further research and development”. activa Calcium Chews brand. Ellactiva is cur- According to Oxford Nutrascience, its deliv- rently available in the UK through retailer Al- ery systems based on prebiotic soluble fibres: liance Boots and in the Middle East through ■ Disperse and solubilise medicines Hauora Products. ■ Improve taste and mouth feel Theobald pointed out that “taking calcium ■ Simplify processing and eliminate additives supplements can often be difficult due to the ■ Incorporate prebiotic health benefits unpleasant chalky taste of the supplement”. In terms of intellectual-property protection, For this reason, he added, Ellactiva had been the company said its technology was the sub- developed with a “unique blend of calcium ject of two patent applications, both initially Nigel Theobald, chief executive officer of Oxford carbonate and milk minerals to create better- filed in the UK. One covers the confectionery Nutrascience, says the company’s new delivery tasting chews”. composition while the other involves the deliv- systems can improve the taste and feel in the mouth of food supplements and OTC medicines Oxford Nutrascience plans to expand be- ery systems. yond calcium chews this year. Theobald said Theobald maintained Oxford Nutrascience’s liquid suspensions, Theobald said these were the company had developed a range of forti- chewy confectionery was a “great format for suitable for OTC medicines, particularly for fied confectionery containing omega-3, gluco- unpleasant-to-take supplements, such as large patients and consumers with swallowing dif- samine, cranberry extract and other ingredients. calcium tablets, or children’s supplements”. ficulties. “This is a common problem among These had previously been difficult to deliver “Anyone with young children will know how the elderly and children, but also all age groups in this way, he added, due to taste issues and much easier it is to get kids to take supple- who are ill, in bed or on the go,”he added. degradation of the ingredient in the cooking pro- ments if they enjoy them,”he observed. Theobald noted that the company’s medi- cess. Each chew had the required dose to make cines development work was focused on chew- it an effective supplement, he noted. Could lead to a gritty texture able allergy tablets containing the active ingre- It is still early days for Oxford Nutrascience, Traditional confectionery chews were made dient loratadine, as well as suspensions con- which through the Ellactiva brand had sales of soft, Theobald noted, by balancing the use of taining ibuprofen. £43,000 (C49,000) in the year ended 31 Dec- crystallising sugars (sucrose) with reducing sug- Chewitabs chewable tablets produce a light ember 2008 and £36,000 in the eight months ars (glucose syrup). Adding minerals to tradi- ‘crunch’ when bitten and then form a soft chew ended 31 August 2009. The company’s operat- tional confectionery chews could lead to a gritty that dissolves quickly in the mouth. This meant ing loss increased from £120,000 in 2008 to texture, he added,as the minerals could change that they could be taken without water,Theo- £174,000 in the first eight months of 2009. the balance and promote crystallisation. bald noted. It was founded in February 2008 by Theo- The taste benefits of using traditional con- Chewitabs are claimed to be suitable for fectionery chews could also be outweighed by convenience-driven OTC medicines – such as the high sugar content, he said, but reducing , allergy treatments and digestive aids the sugar and fat content of a traditional con- – and medicines for the elderly. fectionery chew could compromise both taste They could be manufactured using stan- and texture. dard tablet-compression equipment and pres- Oxford Nutrascience uses a blend of pre- sures, said Theobald, and came in a range of biotic soluble fibres to reduce the sugars and sizes to allow for different doses of ingredi- fat traditionally used to make chews and to pro- ents to be incorporated. vide favourable organoleptic properties. “Our Commenting on its liquid suspensions, Ox- fortified chew is reduced in sugar and fat, and ford Nutrascience notes that gels, syrups and high in prebiotic fibre,”claimed Theobald, “but suspensions are widely used delivery systems Oxford Nutrascience is seeking partners around the with the same soft texture as traditional con- for a range of medicines and nutraceuticals, and world for its Ellactiva Calcium Chews, which are currently only available in the UK from Alliance Boots fectionery chews.” are generally used for children’s analgesics and and in the Middle East from Hauora Products Moving on to the company’s Chewitab and cough and cold medicines. “However, the for-

8 OTC bulletin 26 February 2010 OTC26-02-10p8-9.qxd 23/2/10 12:59 Page 3

COMPANY NEWS OTC

Joint Ventures GNC to form Chinese joint venture firm

eneral Nutrition Centers (GNC) is set to nan Wang, Bright Food’s chairman, who noted subsidiary of Bright Food, will be responsible G launch its nutritional supplements brands that China’s expanding gross domestic product for undertaking the collaboration with GNC. in China, after signing a memorandum of under- and consumer spending had opened up “tremen- Commenting on the joint venture, Junjie Ge, standing to form a strategic partnership with the dous growth opportunities for nutritional prod- vice-president of Bright Food and chairman of Chinese state-owned company Bright Food. ucts” in recent years. Shanghai Yantang, said it would not only intro- The joint venture – called GNC China – The tie-up with GNC marked Bright Food’s duce GNC products into China, but the deal would be formed and would launch products formal entry into the nutritional products arena, would also help “improve and upgrade” select- by mid-2010, the US-based global retailer of Wang noted, adding a new sector to its estab- ed Bright Food products. nutritional supplements said. lished operations which cover a full range of “The GNC partnership in the nutrition in- Joe Fortunato, chief executive of GNC, said fresh and processed foodstuffs. dustry is expected to be a core focus for Bright the firm believed there were “significant growth Food,”Ge said, “and a key growth driver for opportunities” in the Chinese nutritional-prod- State-owned conglomerate our business.” ucts market and was looking forward to working Described by GNC as a “leading state-owned GNC markets a range of more than 1,000 with Bright Food, which had “strong product, conglomerate”, Bright Food is a subsidiary of nutritional products, including vitamin, min- distribution and retail capabilities in China”. Shanghai Municipal Government and its Assets eral, herbal and other speciality supplements, He said the joint venture would also bene- Supervision and Administration Commission. as well as sports nutrition, diet and energy pro- fit from a key Chinese government initiative to Bright Food owns four listed companies and ducts. Its products are sold in over 47 coun- focus on health and wellness. GNC China and a number of well-known Chinese brands, as tries around the world. As of 30 September the company hoped to “help raise levels of well as about 4,000 retail stores and a wholesale 2009, GNC had more than 6,700 retail loca- health awareness in China”, Fortunato added. distribution network stretching across China. tions – 5,300 of which were in the US – and Fortunato’s comments were echoed by Zong- Shanghai Yantang Group, a wholly-owned franchise operations in 47 countries. OTC

mulation of these medicines poses a number of challenges including dispersing hydrophobic ingredients, maintaining stability and provid- ing for acceptable organoleptic properties,”the company says. “Typically,formulations use a range of dispersants and stabilisers and also tend to have sugars or sweeteners added to them for flavour enhancement.” The company claims it has developed a sus- pension system for delivering medicines and nutraceuticals without the need for traditional surfactant and stabiliser ingredients. “Our sus- pension system not only remains stable over time but is also adequately preserved,”says the company. “It is based on soluble fibres that are naturally sweet, so the need for extra sweet- eners is minimised or,in some instances, can be avoided altogether.” “Moreover, given the ability of our delivery system to effectively wet and disperse hydro- phobic ingredients,”adds the firm, “it could be manufactured via a one-step mixing process which is simpler and may offer cost savings relative to a multistep process.”

■ For more information contact Nigel Theobald, chief executive officer,Oxford Nutrascience Group, Centre for Innovation & Enterprise, Oxford University,Beg- broke Science Park, Sandly Lane, Yarnton, Oxford- shire OX5 1PF,UK(Tel: +44 1865 854874; Email: [email protected]). OTC

26 February 2010 OTC bulletin 9 OTC26-02-10p10-11.qxd 23/2/10 13:01 Page 2

OTC COMPANY NEWS

Annual Results Nine-Month Results Pharmstandard benefits Consumer sales as leading brands grow drop at Takeda onsumer Healthcare turnover at Japan’s C Takeda Pharmaceutical dropped back by ales of OTC products by Russia’s Pharm- pensive unbranded generic products. 6.1% to ¥47.0 billion (C 379 million) in the Sstandard increased by 43% to RUB14.8 bil- Sales of Pharmstandard’s unbranded OTC nine months ended 31 December 2009. lion (C360 million) in 2009, as eight of the products increased by 39% to RUB2.1 billion The decline in Consumer Healthcare’s sales company’s top-selling OTC brands posted dou- in 2009. This was not enough, however, to out- was blamed on a fall in sales of the Nicorette ble-digit growth. pace the company’s OTC brands, which fin- smoking-cessation brand, and lower turnover As Figure 1 shows, the anxiety treatment ished ahead by 44% to RUB12.7 billion. from four of the firm’s five best-sellers. Afobazol led the way with sales more than dou- Quoting data from market researcher Pharm- Alinamin vitamin products – the company’s bling to RUB531 million over the 12 months. expert, Pharmstandard said that in 2009 it was biggest-selling Consumer Healthcare line – The flu treatment Arbidol remained Pharm- the number one company in the commercial had a mixed nine months, with sales of Alina- standard’s leading OTC brand, with sales more segment of Russia’s pharmaceutical market, min tablets dropping by 0.8% to ¥11.9 billion, than doubling to RUB5.5 billion. Earlier in the with a market share of 5.5%, up from 5.2% in while the tonic variant posted turnover up by year,Pharmstandard claimed that Arbidol had 2008. The commercial segment accounts for 1.2% to ¥9.7 billion. been proven effective for the prevention and around 75% of the total Russian pharmaceuti- Takeda’s third-biggest seller,the Benza cold treatment of H1N1 swine flu by “major Rus- cal market, with the hospital and federal reim- remedies range – excluding the drink variant – sian virology centres”. bursement segments accounting for the rest. reported a 6.5% decline in sales to ¥6.9 billion. Sales of the Pentalgin grew by Meanwhile, sales of the Biofermin gastroin- 33% to RUB2.1 billion, making it the com- Ahead of international companies testinal brand fell by 6.6% to ¥5.0 billion, and pany’s second-biggest seller in 2009, with the Pharmstandard’s market share puts it ahead sales of Borraginol haemorrhoid products drop- Complivit vitamin brand ranking third after of the international companies Bayer Health- ped by 6.0% to ¥3.1 billion. posting sales up by 77% to RUB1.2 billion. care with a 3.7% share, Berlin-Chemie with a Benza, Biofermin and Borraginol, along The company’s top 10 best-selling brands in 3.7% share, Sanofi-Aventis with a 3.6% share with the two Alinamin variants generated 78% 2009 had reported sales growth of 43.9% in and Sandoz with a 3.2% share. – ¥36.6 billion – of Takeda’s Consumer Health- value terms, Pharmstandard pointed out, while OTC products accounted for 62% of Pharm- care sales in the period. in volume terms the growth had been 12.4%. standard’s total sales, which finished ahead by OTC Commenting on the Russian pharmaceutical 68% to RUB24.1 billion. Sales of third-party market, Pharmstandard said less disposable in- brands and other prescription products were come had led consumers to turn to “old fash- over four-times larger at RUB6.23 billion. IN BRIEF ioned and traditional drugs” as well as less ex- OTC ■ MEDA said sales of its Betadine antiseptic had grown by 13% to SEK898 million (C 91.2 Business Annual sales Change Proportion million) in 2009. Betadine’s sales had improved (RUB millions) 2008/2009 (%) of total (%) in major southern-European markets, except for Arbidol 5,503 +102 23 Spain where annual sales had declined in local Pentalgin 2,100 +33 9 currency terms. Meda’s total turnover grew by Complivit 1,188 +77 5 23% to SEK13.2 billion, while operating profit Terpincod 889 -45 4 rose by 26% to SEK2.90 billion. Codelac 752 +12 3 Flukostat* 649 +17 3 ■ ORION’s sales of its Burana ibuprofen pain reliever increased by 2.4% to C 19.9 mil- Afobazol 531 +144 2 lion in 2009. Burana’s fourth-quarter sales grew Amixin 507 +60 2 by 7.5% to C 5.7 million. Orion’s total sales for Corvalol 222 -6 1 2009 rose by 8.5% to C 772 million. Operating Ingalipt 199 +55 1 profit improved by 11.9% to C 207 million. Other OTC brands 170 –– Unbranded OTC products 2,131 +39 9 ■ IPSEN said sales of its Ginkor Fort ginkgo Total OTC products 14,841 +43 62 biloba brand had dropped by 15.9% to C 12.0 Prescription drugs 2,338 +72 10 million in 2009. Ipsen supplies the non-pre- Third-party prescription drugs 6,228 +310 26 scription brand to GTF Group – which acquir- Medical equipment & disposables 689 -36 3 ed the rights to the product in France, Monaco and Andorra in 2007 (OTC bulletin,31 Aug- Total Pharmstandard 24,096 +68 100 ust 2007, page 1) – but still markets the brand * Tablets only outside this region. Figure 1: Sales by Pharmstandard’s top 10 OTC brands in 2009 (Source – Pharmstandard) OTC

10 OTC bulletin 26 February 2010 OTC26-02-10p10-11.qxd 23/2/10 13:01 Page 3

COMPANY NEWS OTC

Business Strategy Mergers & Acquisitions Ransom drops SSL International delays Medibee brand taking full control of BLBV illiam Ransom & Son has terminated W its supply and licensing agreement for SL International is set to increase its major- will become the company’s group commer- the Medibee honey brand, cutting the com- Sity stake in eastern European condom dis- cial director (see page 23). pany’s portfolio of honey-based products for tributor Beleggingsmaatschappij Lemore BV SSL has built up its stake in BLBV over the the second time in less than a month. (BLBV) from 50% plus one share to 75%, but past two years. In February 2008, the company Under the terms of the termination agree- will now wait until 2011 to purchase the re- paid £24.8 million (C28.5 million) for 15.5% of ment with Bee & Herbal New Zealand – a sub- maining 25%. BLBV,which packages and distributes condoms sidiary of Comvita UK – the troubled UK nat- The new timetable for acquiring BLBV’s and medical products – including the condom ural healthcare products company said it would total share capital replaces the original option brand Contex – in the CIS, excluding the Uk- receive a total cash consideration of £0.36 mil- SSL had agreed when it first bought into the raine (OTC bulletin,29 February 2008, page 3). lion (C 0.41 million), with £60,000 of the cash firm in 2008. This could have seen the UK- Just over a year later,SSL increased its stake to dependent on performance-related conditions. based firm take full control of BLBV this year. 50% plus one share for a further C70 million The money would be used to reduce Ransom’s Explaining the change, SSL said the new (OTC bulletin,17 April 2009, page 2). borrowings. agreement would incentivise BLBV’s manage- The new agreement will see SSL pay no This year,Ransom has already sold its hon- ment team – who are shareholders in BLBV’s more than £140 million to lift its holding from ey-based Manuka Gold brand to Honey New minority stakeholder Abraca – by “extending 50% plus one share to 75%. The price is based Zealand (International) for £0.56 million (OTC their equity participation” in the business for a on a multiple of BLBV’s earnings before inter- bulletin,10 February 2010, page 13). further 12 months. This would help enable the est, tax and depreciation (EBITDA). Explaining the reasons for the termination, successful integration of BLBV into SSL, the A spokesperson for SSL told OTC bulletin Ransom said that although the Medibee prod- company added. that the significant difference between what SSL ucts generated sales of £1.7 million and a gross As part of the integration process, Konstantin was paying for this latest stake and what it had profit of £0.4 million in the year ended March Kirsenko, BLBV’s general director,has agreed paid previously was a result of the speed at 2009, in the year-to-date increased material to join SSL as general director,Russia and the which BLBV’s EBITDA was growing. prices and less promotion had significantly re- Commonwealth of Independent States (CIS). BLBV’s 2009 sales in US dollar terms were duced sales and gross margin. Kirsenko will report to Ian Adamson,cur- expected to have grown by 50% since 2007, Terminating the agreement with Bee & Her- rently SSL’s managing director Europe and while its EBITDA was anticipated to be in ex- bal New Zealand is part of Ransom’s turn- Americas, who with effect from 1 April 2010 cess of US$50.0 million (C36.7 million). around plan to repay its debts. Ransom said OTC it had reduced its term loan from £2.6 million in March 2009 to £0.48 million. This would now be converted into an overdraft facility, Ransom noted. OTC

People Merck Consumer head

■ Continued from front page Gourmet Foods, the second-largest manufac- turer of egg rolls in the US. Heller will take charge of one of Merck’s “five primary divisions” in the enlarged com- pany. The others are Global Human Health – including prescription, vaccines and biologics business units – Animal Health, Merck Man- ufacturing and Merck Research Laboratories. Prior to the US$41 billion acquisition of its smaller rival Schering-Plough (OTC bulletin, 17 March 2009, page 1), Merck had only an indirect presence in the OTC market through the Johnson & Johnson/Merck Consumer Phar- maceuticals joint venture. OTC

26 February 2010 OTC bulletin 11 OTC26-02-10p12-13.qxd 23/2/10 13:01 Page 2

OTC GENERAL NEWS

Switches New Zealand could switch calcipotriol

opical medicines containing calcipotriol tention to a systematic review published in the spray – are already available as pharmacist-only Tcould soon be available without a prescrip- BMJ,which reported that calcipotriol was “sup- medicines in New Zealand. tion in New Zealand for treating psoriasis. erior to calcitriol, coal tar,combined coal tar Merck & Co pointed out that Maxalt Melt OTC bulletin understands that New Zeal- 5%, allantoin 2% and hydrocortisone 0.5%, was supplied as an orally-disintegrating tablet and would be the first country in the world to short contact dithranol and tacalcitol”. Topical that could be taken without water. The comp- switch topical calcipotriol from prescription- calcipotriol was significantly more effective than any noted that the format was more palatable only to non-prescription status. Although Ger- potent topical steroids at six weeks of treatment, to some people than conventional oral tablets. many’s Expert Committee for Prescription re- but not at eight weeks, the company points out. The committee will also consider applica- commended switching topical calcipotriol in “The review concluded that calcipotriol is tions to reclassify Johnson & Johnson’s Imod- 2008, it remains a prescription medicine in the an effective and well tolerated treatment for ium (2mg loperamide) antidiarrhoeal, Johnson country (OTC bulletin,30 June 2008, page 1). mild to moderate chronic-plaque psoriasis,” & Johnson’s Regaine for Men (5% minoxidil) comments Pharmacybrands. “Although skin irri- hair-regrowth product and Reckitt Benckiser’s Retailer Pharmacybrands behind move tation is comparatively common, this rarely re- Strepfen (8.75mg flurbiprofen) sore-throat loz- The Medicines Classification Committee in quires withdrawal of calcipotriol treatment.” enges from pharmacist-only to general-sale med- New Zealand will consider a switch application Currently,topical calcipotriol is available in icines in New Zealand. from retail group Pharmacybrands – the parent New Zealand from CSL as the prescription-only company in New Zealand of Amcal and Uni- medicine Daivonex. It is manufactured by Leo Reverse-switch for cough/cold medicines chem – at its next meeting on 13 April 2010. Pharmaceutical Products, and has been avail- In addition, New Zealand’s regulatory auth- Pharmacybrands wants to reclassify smaller able in New Zealand for over a decade. ority,Medsafe, wants to reverse-switch cough packs – 30g for cream and ointment or 30ml Also on the agenda for the next meeting of and cold medicines containing dextromethor- for scalp application – as restricted, pharma- New Zealand’s Medicines Classification Com- phan, , ipecacuanha or phenyleph- cist-only medicines. They would be restricted mittee is an application from Merck & Co to rine from general-sale medicines to either phar- to adults with mild to moderate psoriasis pre- switch 5mg rizatriptan wafers to pharmacist- macy-only or pharmacist-only status. The move viously diagnosed by a doctor. The strength only status for the treatment of acute migraine was recommended by its Cough Cold Review would be 50µg/g for cream and ointment, and with or without aura. Group, which said the risk-benefit balance for 50µg/ml for scalp application. Two triptans – GlaxoSmithKline’s sumatrip- these products was unfavourable for children In its submission, Pharmacybrands draws at- tan tablets and AstraZeneca’s zolmitriptan nasal under six years of age. OTC

Trade Associations IN BRIEF ■ HEALTH CANADA has approved a switch cussion website at www.medinfodiscussion. US CRN extends of 150mg fluconazole formulations to non-pre- org, asks consumers and healthcare profession- scription status as oral treatments for vaginal als whether they think it is a good idea to make reach to Europe thrush. The switch takes effect in March. the MHRA’s database of Patient Information Leaflets (PILs) and Summaries of Product Char- he US-based Council for Responsible Nut- ■ THE KOREAN Food and Drug Adminis- acteristics (SPCs) available online. The discus- Trition (CRN) has set up an international tration (KFDA) approved 1,986 OTC drugs in sion runs until 8 March 2010. subsidiary based in Manno, Switzerland. 2009, according to a report in Pharma Kore- The dietary supplement trade association ana,compared with 824 prescription drugs. ■ MHRA – the UK’s Medicines and Health- said that the move formalised “the work it has Pharma Koreana said that it was the first time care products Regulatory Agency – has added been doing for decades by standing up for sci- since 2001 that OTC drug approvals had out- a section for the pharmaceutical industry to ence-based principles for dietary/food supple- numbered prescription drug approvals. its website. ments worldwide”. The wholly-owned subsidiary will be called ■ PROCTER & GAMBLE said a study pub- ■ NBTY’s sales improved by 18% to US$228 the Council for Responsible Nutrition-Inter- lished in the British Journal of Dermatology million (C 169 million) in January of this year. national (CRN-I). Its board will be announced showed its Olay Professional Pro-X cosmetic Growth was driven by a 22% rise in turnover at the first CRN-I annual meeting scheduled product improved the appearance of facial at the US-based company’s Wholesale/US Nut- for 15 April in Paris, France. lines and wrinkles as well as the prescription rition division to US$132 million. European The CRN said over a dozen companies had medicine 0.02% tretinoin after eight weeks Retail sales increased by 19% to US$54 mil- already signed on to support the CRN-I, and of treatment. lion, while turnover at the North American Re- additional funding was anticipated. tail division finished ahead by 6% to US$18 On 3 July,the CRN-I is running a one-day ■ MHRA – the UK’s Medicines and Health- million. The company’s Direct Response/E- scientific symposium on ‘Scientific issues re- care products Regulatory Agency – is seeking commerce division posted sales up by a tenth lated to Codex goals’ in Geneva,Switzerland. views on whether key information about medi- to US$23 million. OTC cines should be available online. An online dis- OTC

12 OTC bulletin 26 February 2010 OTC26-02-10p12-13.qxd 23/2/10 13:01 Page 3

GENERAL NEWS OTC

Reformulations Patent Disputes GSK takes zinc Perrigo wins patent case out of Poligrip over Reckitt’s Mucinex laxoSmithKline Consumer Healthcare has Gstopped making and supplying its zinc- containing denture adhesives, including several errigo moved a step closer to the US launch the 12-month period ended January 2010. Poligrip products, across many countries. P of a generic version of Reckitt Benckiser’s Perrigo filed an ANDA with a patent chal- In a “Consumer Advisory” released on 18 Mucinex cough medicine when a federal court lenge against Mucinex in 2007, but Adams Re- February,the company said it had taken the threw out the UK-based company’s patent-in- spiratory Therapeutics – which is now part of voluntary action because of potential health fringement complaint. Reckitt Benckiser – responded by suing Per- problems associated with the long-term exces- The Michigan district court granted Perrigo rigo for patent infringement (OTC bulletin,12 sive use of its zinc-containing denture adhe- summary judgement in litigation over the store- October 2007, page 9). sive products. It stressed that the products brand specialist’s 600mg guaifenesin extend- Earlier in 2007, Adams had settled a pat- remained safe when used as directed on the ed-release tablets. It said Perrigo’s generic did ent challenge to the Mucinex brand from URL/ product label. not infringe the Mucinex patent. Mutual, which potentially kept URL/Mutual’s GlaxoSmithKline said it would change to Perrigo is now waiting for the Abbreviated 600mg guaifenesin product off the market in zinc-free formulations, and packaging would New Drug Application (ANDA) for its generic the US until 2012 (OTC bulletin,30 March clearly state the products were “zinc-free”. product to be approved by the Food and Drug 2007, page 11). Administration (FDA). Perrigo’s victory,however,means that URL/ May lead to neurological symptoms At the start of February,Perrigo’s chairman Mutual may soon be in a position also to launch In the US – where the company may face and chief executive officer,Joseph Papa, said its extended-release 600mg guaifenesin prod- legal action – GlaxoSmithKline is warning Perrigo expected approval from the FDA for uct, as the company’s settlement with Adams consumers about the Original, Ultra Fresh and its store-brand Mucinex within the next 30-60 allowed it to launch if a third party was in a Extra Care versions of Super Poligrip. “While days and that the product would be available position to introduce its own generic guaife- zinc is an essential part of the diet, recent pub- before the close of the company’s financial year nesin product before 1 July 2012. lications suggest that an excessive intake of ending June 2010 (OTC bulletin,10 February Reckitt Benckiser is also defending its Muc- zinc-containing denture adhesives over several 2010, page 10). inex, Mucinex D (pseudoephedrine hydrochlo- years may lead to the development of neuro- Quoting data from AC Nielsen, Perrigo said ride/guaifenesin) and Mucinex DM (dextro- logical symptoms,”states the company. “These Mucinex 600mg extended-release tablets had methorphan/guaifenesin) products from patent may include numbness, tingling or weakness generated sales of approximately US$162 mil- challenges made by generics company Wat- in the arms and legs, difficulties with walk- lion (C119 million) through food, drug and mass son Pharmaceuticals (OTC bulletin,19 June ing and balance, and blood problems.” merchandiser retail outlets in the US during 2009, page 12). OTC OTC

Switches (DDD). That included more than 1.4 million packs, or 15 million DDD, of topical diclo- Ratiopharm seeks UK patch switch fenac, mainly as gel. The 140mg diclofenac patches are already atiopharm has applied to switch its Al- If switched, Algopain-Eze will be available available without a prescription in Austria, Ger- R gopain-Eze 140mg diclofenac patch – or in a maximum pack size of 14 patches, which many, Italy and Slovakia. “medicated plaster” – from prescription-only is enough for one week’s treatment with up to Ratiopharm – which already markets the pro- to pharmacy status in the UK. two analgesic patches per day. biotic food supplement Life’s-Biotic in the UK In its ARM 65 consultation document, the The MHRA notes topical diclofenac gels ( OTC bulletin,15 May 2009, page 15) – plans UK’s Medicines and Healthcare products Reg- have been available in the UK since 1997. Nov- to introduce specific OTC packaging and phar- ulatory Agency (MHRA) says that “the adverse artis Consumer Health’s Voltarol Pain-eze Emul- macy training materials to support the switch. event profile of the medicated plaster has been gel, for example, is classified as a general-sale Having undergone a European Union mut- shown to be comparable to gel formulations medicine for adults and children aged 12 years ual-recognition procedure for Algopain-Eze, and significantly improved compared to oral and older (OTC bulletin,30 June 2004, page Ratiopharm holds authorisations for its patches treatment”. 5). Novartis also offers a prescription-only gel under various brand names in Austria, Belgium, patch and unlicensed heat patches under the the Czech Republic, Denmark, Germany, Hun- Amenable to self-diagnosis Voltarol brand in the UK. gary,Italy,Poland, Slovakia, Spain, Sweden The proposed indication for adults and chil- Diclofenac medicated plasters have been and the UK. The German firm holds similar dren aged above 14 years – “local symptomatic authorised as a prescription medicine since authorisations in France, Poland and Portugal treatment of pain in acute strains, sprains or bru- 2004, the agency observes. from a separate mutual-recognition procedure. ises of the extremities following blunt trauma, In 2008, nearly nine million packs of diclo- The MHRA is inviting comments on the such as sport injuries” – is “closely defined and fenac products were dispensed in the UK, equat- proposed switch until 25 March 2010. amenable to self-diagnosis”, it states. ing to nearly 90 million defined daily doses OTC

26 February 2010 OTC bulletin 13 OTC26-02-10p14-15.qxd 23/2/10 13:03 Page 2

Published20timesayear, OTC bulletin is suppliedinaprintedformatdesignedtoprovide you with aregular briefing on the business of consumer healthcare. Yo ur annualsubscriptionalsooffersthe addedvalue of news@OTCbulletin –afreeweekly*electronicnewsflash whichkeeps you fully updatedwith thebiggest storiesbreakinginthe consumer healthcaresector.

*Published around 45 times ayear SUBSCRIPTION FORM

PLEASE TICK APPROPRIATE BOXES DELIVERYADDRESS

Iwould like ______annual subscription/stoOTC bulletin at therate of ❏ Name______Position______£595 (£625outside Europe) for single copies and £345 (£375 outsideEurope) foradditional copies to the same address Company ______PAYMENT OPTIONS Address______Ienclose acheque for £______, or the equivalent in Euros ______, drawn on aUKbank ❏ ______Cheques should be made payable to OTC Publications Ltd ❏ Please send me an invoice ______Please debit my credit card for £______❏ Tel______Fax ______❏ VISA ❏ MASTERCARD ❏ AMERICAN EXPRESS E-mail address for news@OTCbulletin ______Card No: Please returnformto:

Three/four-digit security code: OTC bulletin,Bulletin Publishing Group, OTCPublications Ltd, 54 Creynolds Lane, Solihull B90 4ER, UK. Or Faxto: +44 (0)1564 777524 Cardholder signature ______Telephone enquiries: +44 (0)1564 777550 E-mail: [email protected] Expirydate: ______Date ______Registered Office: As above.Registered in England No 2765878. VATNoGB608 0432 69

For more information visit our website at www.OTC-bulletin.com OTC26-02-10p14-15.qxd 23/2/10 13:04 Page 3

MARKETING NEWS OTC Mix-upsRegulatory Affairs make Novartis rename Maalox variant

ovartis Consumer Health has agreed to re- According to the FDA, the active ingredi- Nname one of its Maalox products in the US, ent of Maalox Total Relief, bismuth subsali- following five reports that product mix-ups had cylate, was chemically-related to aspirin and led to serious errors. The company could cause similar harmful side-effects such will also change the pack design to avoid fur- as bleeding. The regulatory agency said Maalox ther confusion. Total Relief was not appropriate for individu- The Food and Drug Administration (FDA) als who wanted to use an antacid, especially if said consumers had mistakenly taken Maalox they had a history of gastrointestinal ulcer dis- Total Relief, the upset stomach reliever and ease or a bleeding disorder. antidiarrhoeal medicine, when they had intend- The FDA added that Maalox Total Relief ed to use the traditional liquid antacid products, should not be taken by children and teenagers Maalox Advanced Regular Strength or Maalox if they were recovering from a viral infection. Melt-in-the-mouth capsules are the latest addition to Advanced Maximum Strength. Nor should it be taken by individuals who were Nelsons’ Rescue Night brand in the UK. Carol Holquist, director of the FDA’s Divi- taking certain including oral anti- The company said Rescue Night Liquid Melts, sion of Medication Error Prevention and An- diabetes drugs; anticoagulation drugs, such as which are positioned as “the easy way to take Rescue Night”, contained the familiar combination of alysis,said consumer confusion and incorrect warfarin and clopidogrel; and non-steroidal and five flower essences plus the Bach Original Flower product use due to name confusion were “seri- other anti-inflammatory drugs. Essence white chestnut. “White chestnut helps free ous public health issues”. On 17 February,the FDA warned consum- the mind from fretful and repetitive thoughts,” commented the company, adding that this was “The FDA is concerned about the public ers about the potential for serious side-effects “perfect if you struggle to wind down after a hectic health impact of medication mix-ups for pro- from mistakenly using Maalox Total Relief in- day in the office or if you have been burning the ducts that have the same names or portions of stead of other Maalox products. The two prod- candle at both ends”. A pack of 28 capsules has a recommended retail the same name, but contain different active in- ucts were intended for the relief of different selling price of £7.95 (C 9.10). A strapline on the gredients,”commented Holquist, adding: “We symptoms and contained different active ingre- packaging urges consumers to “Dissolve on your want companies to consider the potential for dients, said the FDA. tongue for a natural sleep”. The newcomer joins the existing Rescue Night name confusion when choosing drug names.” As well as changing the name and packag- dropper and spray formats. The renamed product is expected to reach ing of Maalox Total Relief, Novartis has agreed The Rescue portfolio also includes Rescue stores in September 2010. In the meantime, the to carry out an educational campaign aimed at Chewing Gum, Rescue Remedy, Rescue Cream and Rescue Pastilles. FDA is advising consumers and healthcare pro- healthcare professionals and consumers. This Nelsons noted that it had been supplying natural fessionals to check the labels of all Maalox pro- will cover different Maalox products and ways healthcare products since 1860, making 2010 its ducts very carefully. to select the appropriate variant in the range. 150th birthday. Holquist pointed out that “Maalox Total Re- The company will also actively monitor and re- OTC lief and Maalox were not interchangeable and port adverse events associated with the use of should not be used in place of each other”. Maalox products. IN BRIEF OTC ■ ASA – the UK Advertising Standards Auth- ority – has upheld a complaint about a direct Product Launches mailing for Stirling Health’s Nytric EFX. The mailing included the phrase “the only safe, Spain’s Cinfa targets skincare natural and totally effective alternative to Via- gra”, and described the unlicensed product as aboratorios Cinfa is pushing into a new area claims is the country’s first balm “amazing aphrodisiac pills”. The ASA noted Lof business by launching a dermopharmacy in stick form. The Respirub brand comes in Stirling had not responded to its enquiries. line under the Be+ brand. two versions: one for children containing ex- The Spanish company, which currently has tracts of eucalyptus, pine and lavender; and ■ ASA – the UK Advertising Standards Auth- generics, OTC and orthopaedic units, plans to another for adults with eucalyptus, menthol and ority – has upheld complaints from Holland invest C 25 million in the skincare project over camphor. A 50ml stick retails at C 5.25. & Barrett and a member of the public about the next five years. Last year,Cinfa increased its sales by 14.5% two brochures for food supplements produced Cinfa has to date launched 19 products und- to C 183 million. by Healthy Direct. The authority has also up- er five Be+ ranges – acne, anti-ageing, atopics, In 2010, it intends to raise group sales – in- held a complaint from Holland & Barrett about men and moisturising. cluding exports to more than 30 countries – by two brochures for food supplements publish- Meanwhile, Cinfa has also strengthened its about 12% to C 205 million. ed by Healthspan. OTC presence in Spain by rolling out what it OTC OTC

26 February 2010 OTC bulletin 15 OTC26-02-10p16-17.qxd 23/2/10 13:05 Page 2

OTC MARKETING NEWS Alli ascends as Flomax enters rankings

Flomax Relief makes its first appearance – behind Alli, Benylin and NiQuitin – in our monthly Pharmacy viewpoint rankings of UK pharmacists’ attitudes to OTC sales and marketing, which are published exclusively in OTC bulletin courtesy of the Intr@PharmQ service from IMS.

nitial promotional activity for Boehringer Agency (MHRA) approved the switch of 0.4mg IIngelheim’s Flomax Relief has caught the tamsulosin hydrochloride capsules from pre- eye of pharmacists in the UK, according to our scription-only to pharmacy (POM-to-P status) Pharmacy viewpoint survey for February. Flo- for treating lower urinary-tract symptoms in McNeil’s Benylin cough medicines top the television max Relief makes its first appearance in the men aged between 45 and 75 years. rankings for the third time in a row rankings for trade-press advertising, pharmacy- The company said recently that Flomax Re- support package and representative detailing. lief would be available in pharmacies from- after its launch in the UK in early 2009. The focus of the initial promotional activity March. Boehringer Ingelheim will back the in- Last month, however, GlaxoSmithKline in- is pharmacy training, public relations activity, troduction with a “high-profile” marketing cam- troduced a fresh pharmacy-press advertising and advertising in the pharmacy press. The last paign including consumer advertising, public campaign. This highlights new data showing of these urges pharmacy staff to “Help men relations activity and point-of-sale items, which that “taking Alli while following a reduced- take control of their annoying pee problems”, will commence in late March or early April calorie, lower-fat diet can lead to a significant and shows a product pack flattening an animat- (OTC bulletin,20 January 2010, page 10). reduction not only in weight but also in dan- ed letter ‘P’ complete with arms and legs. The best performer in the February survey gerous visceral fat”. In December,the UK became the first coun- was GlaxoSmithKline Consumer Healthcare’s The advertising includes a magnetic reso- try in the world to make Flomax a non-pres- Alli weight-loss medicine, which ranked either nance imaging scan showing visceral fat inside cription medicine for treating benign prostatic first or second in all four sections of Pharm- the body of an obese individual. It points out hyperplasia, or an enlarged prostate (OTC bul- acy viewpoint (see Figures 1, 2, 3 and 4). Alli that “there is a clear relationship between ex- letin,18 December 2009, page 1). The UK’s had slipped down the rankings in recent sur- cess visceral fat and the risk of type 2 diabetes Medicines and Healthcare products Regulatory veys following a long period of dominance and cardiovascular disease”. When IMS Consumer Health surveyed phar- BEST CURRENT REPRESENTATIVE DETAILING macists between 1 and 17 February 2010 using Rank Brand Company Product type Pharmacists (%) its Intr@PharmQ service, one in five said Alli was backed by the best current trade-press ad- 1NiQuitin GlaxoSmithKline Smoking-cessation aid 17.8 vertising for an OTC medicine or dietary sup- 2Alli GlaxoSmithKlineWeight-loss medicine 7.8 plement (see Figure 1). A similar proportion felt the same way about the pharmacy-support 3Nicorette McNeil Products Smoking-cessation aid 6.7 package for Alli (see Figure 3). 4Nurofen Reckitt Benckiser Oral/topical analgesic 4.4 In the television-advertising section, the hon- ours went to McNeil Products’ Benylin brand 5= Flomax Boehringer Ingelheim Benign prostatic hyperplasia 3.3 for the third time in a row (see Figure 2). Many Reckitt Benckiser Cough/cold remedy 3.3 pharmacists referred specifically to the com- Nicotinell Novartis Smoking-cessation aid 3.3 mercial for Benylin Mucus Cough. Seven Seas Seven Seas Food supplement 3.3 In the representative detailing section, Glaxo- Base: 90 pharmacists who named a brand of OTCmedicine or food supplement SmithKline’s NiQuitin nicotine-replacement therapies led the way for the third month in a Figure 4: Unprompted response of UK pharmacists between 1 February and 17 February 2010 when they were asked the question: “In your opinion, which OTC medicine/dietary supplement is currently backed by the row (see Figure 4). best representative detailing?” (Source – OTC bulletin/IMS’ Intr@PharmQ service) OTC Intr@PharmQ and Pharmacy viewpoint

harmacy viewpoint is a monthly survey reflecting their general feelings about partic- The service can be used to ask pharmacists Pof pharmacy attitudes to OTC marketing ular OTC brands. about a range of subjects including products, in the UK, which appears exclusively in OTC Intr@PharmQ is a rapid information-gath- company image and representatives. OTC bulletin courtesy of the Intr@PharmQ service ering service consisting of web-based interac- from IMS. tive questionnaires on the Intr@Pharm com- ■ For further information contact Tai Azeez, IMS, 7 The survey highlights pharmacists’ attitudes munity pharmacy portal. Questionnaires can Harewood Avenue, London NW1 6JB, UK (Tel: +44 to OTC marketing campaigns – both as health- be set up on the site quickly,and responses col- 20 3075 4142; Fax: +44 20 7393 5900; E-mail: TAzeez care professionals and consumers – as well as lated within days. @uk.imshealth.com).

16 OTC bulletin 26 February 2010 OTC26-02-10p16-17.qxd 23/2/10 13:05 Page 3

MARKETING NEWS OTC PHARMACY viewpoint

BEST CURRENT TRADE-PRESS ADVERTISING Rank Brand Company Product type Pharmacists (%)

1Alli GlaxoSmithKlineWeight-loss medicine 20.0 2NiQuitin GlaxoSmithKline Smoking-cessation aid 14.4 3Benylin McNeil Products Cough/cold remedy 8.9 4= Full Marks SSL International Head-lice remedy 5.6 Nicorette McNeil Products Smoking-cessation aid 5.6 Nurofen Reckitt Benckiser Oral/topical analgesic 5.6 7Flomax Boehringer Ingelheim Benign prostatic hyperplasia 4.4

GlaxoSmithKline is backing its Alli weight-loss Base: 90 pharmacists who named a brand of OTCmedicine or food supplement medicine with new pharmacy-press advertising Figure 1: Unprompted response of UK pharmacists between 1 February and 17 February 2010 when they were asked the question: “In your opinion, what is the best current trade-press advertisement for an OTC medicine/dietary supplement?” (Source – OTC bulletin/IMS’ Intr@PharmQ service)

BEST CURRENT TELEVISION ADVERTISING Rank Brand Company Product type Pharmacists (%)

1Benylin McNeil Products Cough/cold remedy 13.3 2Alli GlaxoSmithKlineWeight-loss medicine 11.1 3NiQuitin GlaxoSmithKline Smoking-cessation aid 8.9 4Nurofen Reckitt Benckiser Oral/topical analgesic 6.7 5= Canesten Bayer Consumer Care Antifungal 5.6 Nicorette McNeil Products Smoking-cessation aid 5.6 7= Covonia Thornton & Ross Cough/cold remedy 4.4 Gaviscon Reckitt Benckiser Indigestion remedy 4.4 9Lemsip Reckitt Benckiser Cough/cold remedy 3.3

Base: 90 pharmacists who named a brand of OTCmedicine or food supplement

Figure 2: Unprompted response of UK pharmacists between 1 February and 17 February 2010 when they were asked the question: “In your opinion, what is the best current television consumer advertisement for an OTC GlaxoSmithKline’s NiQuitin heads the rankings for medicine/dietary supplement?” (Source – OTC bulletin/IMS’ Intr@PharmQ service) representative detailing for the third time in a row BEST CURRENT PHARMACY-SUPPORT PACKAGE Rank Brand Company Product type Pharmacists (%)

1Alli GlaxoSmithKlineWeight-loss medicine 21.1 2NiQuitin GlaxoSmithKline Smoking-cessation aid 13.3 3Nurofen Reckitt Benckiser Oral/topical analgesic 8.9 4Flomax Boehringer Ingelheim Benign prostatic hyperplasia 7.8 5= Benylin McNeil Products Cough/cold remedy 4.4 Gaviscon Reckitt Benckiser Indigestion remedy 4.4 Nicorette McNeil Products Smoking-cessation aid 4.4 8= Lemsip Reckitt Benckiser Cough/cold remedy 3.3 Meltus SSL International Cough/cold remedy 3.3

Base: 90 pharmacists who named a brand of OTCmedicine or food supplement

Figure 3: Unprompted response of UK pharmacists between 1 February and 17 February 2010 when they Boehringer Ingelheim’s pharmacy-press advertising were asked the question: “In your opinion, which OTC medicine/dietary supplement is currently backed by the for Flomax Relief uses no-nonsense language best pharmacy-support package (consumer/trade advertising, bonus deals, profit margin, training, etc)?” (Source – OTC bulletin/IMS’ Intr@PharmQ service)

26 February 2010 OTC bulletin 17 OTC26-02-10p18.qxd 23/2/10 13:08 Page 2

OTC MARKETING NEWS

Line Extensions Bayer gets intimate with German Canesten range

ntimate-wash products that are “gentler than Isoap and more thorough than water” are the latest addition to Bayer HealthCare’s Canesten antifungal brand in Germany. The company claims that its Canesten Gyn Sensicare lotion and foam have a “synergistic mode of action” through their combination of “Super smooth and great tasting” is Forum Health’s promise to consumers for its new Calci-plus food ingredients – lactic acid, dexpanthenol, lipids supplement in the UK. and lotus-flower extract. Calci-plus chewable tablets have a “unique According to Bayer,the lactic acid helps to spray-dried calcium and magnesium formula that ensures each tablet is super smooth”, says maintain a natural pH balance and thereby pre- Forum Health, adding that there is “less of the vent infections. Dexpanthenol soothes by help- chalkiness associated with other calcium ing the skin to retain moisture, and is support- supplements, making them a more suitable option for some patient groups”. ed by lipids and lotus-flower extract. Both ver- According to Forum Health, Calci-plus provides sions of product are free from artificial colour- the recommended daily allowance of calcium and ings and preservatives. vitamin D, plus 67% of the recommended daily allowance of magnesium. The pink-and-white packs carry a picture of Consumers should take two of the sugar-free a lotus flower together with the strapline “San- Bayer’s new Canesten Gyn Sensicare line of tablets a day. Two tablets contain 800mg calcium, fte und schützende Intimpflege für jeden Tag”, intimate-wash products in Germany comprises a 250mg magnesium, 5µg vitamin D, 10mg zinc, lotion and a foam 0.5mg manganese and 0.6mg boron. which translates as “Gentle and protective inti- A box of 30 tablets has a recommended retail mate care for every day”. and Ireland under the brand name Care by selling price of £4.99 (C 5.69). Bayer said studies it had conducted showed Canesten. Forum Health previously traded as Britannia Health Products. that the lotion and foam were well tolerated Meanwhile, Bayer has updated the packag- OTC and produced no allergic reactions. Further- ing for its entire Canesten range in Germany. more, “97% of women who took part in a trial The company commented that the new packs IN BRIEF would happily use the product in future”, the were “more consumer-friendly” in that they company added. differentiated more clearly between the dif- ■ VIFOR PHARMA POTTERS – the UK Launch trade-press advertising for Canesten ferent products for athlete’s foot, thrush and subsidiary of Switzerland’s Galenica – has ap- Gyn Sensicare, which is available exclusively nail infections. pointed Ceuta Healthcare as its salesforce in from pharmacies, reminds pharmacists that the The Canesten and Canesten Extra creams the UK. The natural healthcare specialist said unlicensed products can be displayed for self- and sprays for athlete’s foot now come in pre- a 20-strong team from Ceuta would support selection by consumers. dominantly blue livery,as do a bifonazole-bas- the independent pharmacy and health food sec- A 200ml bottle of the lotion has a recom- ed nail set and a laundry rinse. Packs of Can- tors. The company noted that the Potters line mended retail price of C11.50. The 150ml foam esten Gyn creams and pessaries for thrush are of herbal medicines would celebrate 200 years dispenser retails at C10.90. predominantly yellow. of business in 2012. A similar cream wash is available in the UK OTC

■ RATIOPHARM UK is backing its Life’s- Biotic probiotic food supplement in the UK with a sales initiative designed to give pharma- cists in excess of 40% profit on return. Phar- macists will receive a free box of Life’s-Biotic sachets with every case of Life’s-Biotic ord- ered, and they can obtain single sachet sam- ples for free distribution to customers. In addi- tion, branded shelf-talkers will be provided to pharmacists. Launched last year,Life’s-Biotic contains five probiotic strains and is available in a choice of powder sachets, liquid vials or capsules. None of the products require refrig- eration (OTC bulletin,15 May 2009, page 15). OTC New packaging for Canesten in Gemany is colour-coded to differentiate between products for different problems

18 OTC bulletin 26 February 2010 OTC26-02-10p19.qxd 23/2/10 13:09 Page 3

EVENTS OTC

APRIL 16 April 19, 20-21 & 22 April ence focusing on nutraceuticals, ■ Medicines Variations ■ Regulatory Affairs in cosmeceuticals, functional foods 15 April Regulation Central and Eastern and functional drinks. ■ Phytopharmaceuticals London, UK Europe Contact: IIR Exhibitions, in Europe This one-day event – organised by Budapest, Hungary 5th Floor,29 Bressenden Place, Bonn, Germany the UK’s Medicines and Health- A pre-conference symposium on London SW1E 5EW,UK. Speakers at this one-day confer- care products Regulatory Agency ‘Regulatory affairs in the CIS re- Tel: +44 20 7017 7026. ence – organised by Germany’s (MHRA) – will focus on the new gion’ and a post-conference work- Fax: +44 20 7017 7818. medicines manufacturers’ associ- European Variations Regulation shop on ‘Practical application of E-mail: [email protected]. ation, the BAH, and conducted in that came into operation on 1 Jan- pharmacovigilance in regulatory Website: www.vitafoods.eu.com. German – will include Werner uary 2010. affairs’ will accompany this two- 30-31 May Knöss of the German federal in- Contact:Conferences and day conference on pharmaceuti- ■ Pharmaceutical stitute for medicines and medical Learning Centre, MHRA, cal regulatory affairs in central and Regulatory Affairs devices, BfArM. 16th Floor,Market Towers, eastern Europe. Contact:BAH, Ubierstrasse 71-73, 1 Nine Elms Lane, Contact:Informa UK, PO Box 406, in the Middle East 53173 Bonn, Germany. London SW8 5NQ, UK. Byfleet KT14 6WL, UK. Dubai, United Arab Emirates Tel: +49 228 957 45 0. Tel: +44 20 7084 2903. Tel: +44 20 7017 7481. Bahrain, Kuwait, Saudi Arabia and Fax: +49 228 957 45 90. Fax: +44 20 7084 3522. Fax: +44 20 7017 7823. other countries in the Middle East E-mail: [email protected]. E-mail: [email protected]. E-mail: [email protected]. will be discussed. Website: www.bah-bonn.de. Website: www.mhra.gov.uk. Website: www.informa-ls.com. Contact: Management Forum, 98-100 Maybury Road, Woking, MAY Surrey GU21 5JL, UK. 9-11 June Tel: +44 1483 730071. ■ 46th AESGP Annual Meeting 18-19 May Fax: +44 1483 730008. Dubrovnik, Croatia ■ Regulatory Affairs E-mail: registrations@management- ‘Connecting with self-care. The future of self-medication in the new Eur- in Africa forum.co.uk. ope’ will be the theme of the 46th Annual Meeting of the Association of London, UK Website: www.management- the European Self-Medication Industry,the AESGP. This two-day event will focus on forum.co.uk. The three-day meeting will include a session entitled ‘How to be suc- pharmaceutical regulatory affairs cessful in self-care’, featuring presentations from Manfred Scheske, pres- in Africa, including South Africa. JUNE ident of GlaxoSmithKline Consumer Healthcare for Europe; Etienne de Contact: Management Forum, Laroullière, vice-president and head of global business unit OTC at Ny- 14-15 June 98-100 Maybury Road, Woking, comed; Cavan Redmond, senior vice-president and group president of ■ EuroPLX 43 Surrey GU21 5JL, UK. Pfizer Diversified Businesses; and Dirk Van de Put, president and chief Berlin, Germany Tel: +44 1483 730071. executive officer,global OTC, at Novartis Consumer Health. A two-day partnering and licens- Fax: +44 1483 730008. Speakers at the meeting will also include: Martin Terberger and Basil ing forum focusing on OTC med- E-mail: registrations@management- Mathioudakis of the European Commission; Thomas Lönngren of the icines, nutraceuticals, branded pre- forum.co.uk. European Medicines Agency (EMEA); Dagmar Roth-Behrendt of the scription drugs and generics. Website: www.management- European Parliament; and Catherine Geslain-Lanéelle and Vittorio Sil- Contact:RauCon, Kurfürstenstrasse 1A, forum.co.uk. ano of the European Food Safety Authority (EFSA). 69234 Dielheim, Germany. Contact:AESGP,7Avenue de Tervuren, 1040 Brussels, Belgium. 18-20 May Tel: +49 6222 9807 0. Tel: +32 2 735 51 30. Fax: +32 2 735 52 22. E-mail: [email protected]. ■ Vitafoods Fax: +49 6222 9807 77. Website: www.aesgp.be. Geneva, Switzerland E-mail: [email protected]. A three-day exhibition and confer- Website: www.raucon.com.

26 February 2010 OTC bulletin 19 OTC26-02-10p20-21.qxd 24/2/10 06:45 Page 2

OTC AESGP MEETING

cedure, two applications have been withdrawn European licensing by the sponsor. Furthermore, several applica- tions to use the centralised procedure for non- prescription medicines have been rejected, and companies have been advised to use the mutual comes under scrutiny recognition or decentralised procedures instead (OTC bulletin,10 February 2010, page 24). As can be seen from Figure 1, just 42 of the A survey by the European OTC industry highlights that firms using Europe’s new applications finalised through Europe’s mutual-recognition and decentralised procedures to license non-prescription mutual-recognition and decentralised licensing procedures in 2009 were for non-prescription medicines face distant starting times and long review periods. medicines. This was just 2.5% of the total num- ber for the year. sing Europe’s mutual-recognition ered 25 market submissions for procedures in- The figures – released by the CMD(h) – clas- and decentralised procedures to lic- volving new applications, and 30 market sub- sify medicines as either prescription or non- ense non-prescription medicines re- missions for post-marketing procedures. prescription by the legal status in the reference Umains a major problem for the in- It was in part a response to discussions with member state for the procedure. dustry. Companies wanting to use the decen- Europe’s Co-ordination Group for Mutual Re- Discussing the AESGP’s initiative,Carpen- tralised procedure generally have to wait two cognition and Decentralised Procedures Human, ter said the survey covered 134 finalised new or three years for a starting-time slot to be of- the CMD(h), about industry’s concerns in the applications, of which 94 were national pro- fered by a reference member state, although light of two smaller AESGP surveys in 2008. cedures and 40 were European mutual-recog- Germany, Italy,Sweden and the UK have re- Presenting the findings earlier this year at nition or decentralised procedures. He observed cently accommodated companies sooner. Fur- a meeting in London organised by the AESGP, that these figures highlighted that the non-pre- thermore, once assessments for non-prescrip- Glenn Carpenter,Johnson & Johnson’s senior scription industry was using the European pro- tion medicines get underway,review times are director of regulatory affairs, said non-prescrip- cedures for new product applications in spite likely to be longer than expected. tion companies were “willing to make more use of the ongoing challenges with queue times for These are two of the main findings of a re- of the mutual-recognition and decentralised the decentralised procedure. cent survey by the Association of the European procedures, but they need more transparency Carpenter said that the survey had found Self-Medication Industry,the AESGP. For the on slot times”. “This is a major concern for in- that queue times for the decentralised proced- survey,eight multinational companies supplied dustry,” he insisted. ure were typically two or three years. He added, the AESGP with data and comments on their Access to the mutual-recognition and decen- however, that there had been some recent ex- recent experiences of using the mutual recog- tralised procedures is particularly important for amples of shorter times in Germany, Italy,Swe- nition and decentralised procedures for non- non-prescription companies, as Europe’s cen- den and the UK (see Figure 2). prescription medicines. This raw data was an- tralised procedure overseen by the European One positive development is that regulatory onymised by the AESGP,and sent to Johnson Medicines Agency offers them limited oppor- agencies have started publicising the availabil- & Johnson for analysis. tunities at present. ity of slots. The UK’s Medicines and Healthcare The survey focused on countries in the Euro- Although two medicines have obtained non- products Regulatory Agency (MHRA), for in- pean Economic Area and Switzerland, and the prescription status in all 27 member states of stance, announced in July of last year that can- period until the end of December 2009. It cov- the European Union using the centralised pro- cellations and delays had left it with “some

450

400 384

350 nalised

fi 300 284 291 257 250

200

150 103 100 67 Number of new applications 41 39 40 50 39 30 16 20 19 4 10 12 2 4 4 1 7 5 3 0 y al ary kia nia Italy UK Latvia Malta va ve Spain Austria Estonia Finland France Iceland Ireland Norway Poland Belgium Denmark German Hung Portug Romania Slo Slo Sweden Netherlands Czech Republic

Figure 3: New applications finalised through Europe’s mutual recognition and decentralised licensing procedures in 2009 by reference member state (Source – CMD(h))

20 OTC bulletin 26 February 2010 OTC26-02-10p20-21.qxd 24/2/10 06:45 Page 3

AESGP MEETING OTC

capacity in all therapeutic areas” to act as the around 360 days, he added, while the average Prescription Non-prescription reference member state for decentralised appli- for European procedures was 310 days. cations (OTC bulletin,31 July 2009, page 17). Moving on to finalised procedures for post- 2009 1,640 42 According to Carpenter,the survey had high- marketing activities, Carpenter said that the 2008 1,102 43 lighted varying degrees of receptiveness across AESGP’s survey covered 557 of these. Nat- 2007 806 27 Europe to applications concerning non-prescrip- ional procedures accounted for 328, compris- 2006 562 30 tion medicines. ing 143 Type IA, 87 Type IB and 98 Type II. 2005 909 45 The reasons given by national regulatory European procedures were 229 of the total, of agencies for not accepting the role of reference which 112 were Type IA, 55 were Type IB and Figure 1: New applications finalised through Europe’s mutual recognition and decentralised member state, he added, included lack of re- 62 were Type II. licensing procedures. Medicines are classified as sources, lack of experience as a reference mem- Carpenter noted that the numbers support- prescription or non-prescription by the legal status in ber state, and lack of experience with the prod- ed the message that the non-prescription indus- the reference member state (Source – CMD(h)) uct presentation. Regulatory agencies also said try was using the European procedures. they were only accepting generic applications Noting that “criteria for IA, IB and II are be simpler,as applications involved well-est- or accepting products in specific disease areas. diverse across the region”, Carpenter said pro- ablished active ingredients with known treat- Carpenter noted that when the problem was cedures were highly variable and, in contrast ment regimes. a lack of resources, one suggestion had been to to procedures involving new applications, nat- He also insisted that the needs of the non- approach other national regulatory agencies. ional procedures appeared to be faster. The ave- prescription industry were different to those But, as he asked, “if others are not prepared to rage review time for a Type IA variation, for of the prescription sector. Non-prescription act as the reference member state, then what is example, was 64 days for national procedures innovation operated on a different timeline to the next option?” versus 110 days for European procedures. The prescription innovation, he said, and there was equivalent figures for Type IB were 95 days less up-front development and discussion. This Three-quarters handled by four countries versus 140 days, while for Type II they were could mean that there was not the same oppor- In 2009, four countries acted as the refer- 155 days compared with 250 days. tunity to obtain “buy-in” from the regulatory ence member state for nearly three-quarters of Carpenter could see no apparent reason why agencies, he observed. the new applications finalised through the mut- national procedures should be faster than Euro- Carpenter added that non-prescription com- ual-recognition and decentralised procedures pean procedures for post-marketing applications panies needed to react quickly to changes in sea- (see Figure 3). but the reverse be the case for handling new sonal needs, such as high incidence of hayfever Looking at review times, Carpenter said that applications. or colds and flu. They also needed competitive comparing national procedures with European He stressed that the findings of the AESGP flexibility and transparency, he said. procedures had revealed some interesting re- survey should not be viewed as either good or In terms of review times, Carpenter noted sults. For the purposes of the survey,the review bad, as the association simply wanted to pre- that the sample for the survey was limited. How- time was defined as submission to approval in sent the experiences of companies. Indeed, he ever,he wondered whether the findings of the days, minus any clock stop. acknowledged that the findings could be af- survey meant that non-prescription medicines There was considerable variability in review fected by many variables, such as the number typically lay at the extremes of the normal times from one country to another,said Car- of applications collated per market and the com- curve. “Do branded and generic prescription penter,and there was a variable difference be- plexity of the applications. medicines more closely fit with the published tween actual review times and published data/ Carpenter pointed out that reviewing non- norms and averages?” he asked. norms. The average for national procedures was prescription medicines should – in the main – OTC

40

35

30

25

20

15 Queue time (months) 10

5

0 y* al aria UK* Italy* Latvia Spain Austria Estonia Finland France Poland Belgium Bulg Republic Hungary Norway Portug Romania Sweden* Denmark German Lithuania Netherlands Czech * Lighter grey bars represent more recent experience

Figure 2: Queue times for companies applying to use Europe’s decentralised procedure to license non-prescription medicines (Source – AESGP)

26 February 2010 OTC bulletin 21 OTC26-02-10p22-24.qxd 23/2/10 13:12 Page 2

OTC PEOPLE

Market Research Agencies Manufacturers Beck steps up Pfizer Consumer Healthcare at IMS Health adds to its leadership team MS Health has given Elisabeth Beck res- Iponsibility for its central Europe region cov- fizer has added to the global leadership team Todd Magazine ering Germany, Switzerland, Austria, Hungary, Pof its newly-acquired Consumer Healthcare Poland, the Czech Republic and Slovakia. operation. It has appointed Todd Magazine to Beck’s previous role as country manager the role of president for the US and Canada, for Germany has been filled by Frank Wart- while Mark Gelbert becomes senior vice-pres- enberg,who previously worked on commer- ident for global research and development. cial effectiveness within the market research Recruited from PepsiCo – where he served agency’s European consultancy arm. as president of the Gatorade & Propel division After studying agricultural economics, Beck – Magazine will run Pfizer Consumer Health- joined IMS Health in 1980. She fulfilled sev- care’s US division and oversee its Canadian eral roles at the market research agency’s Ger- business. Pfizer remarked that these were the man headquarters in Frankfurt, including head unit’s two largest affiliates. of consumer health and OTC, before becom- During his 10 years at PepsiCo, Magazine Mark Gelbert ing country manager for Switzerland in 1997. also served as president and chief executive She returned to the German office in 2002. officer of the company’s Quaker Foods divi- sion as well as its chief marketing officer. Elisabeth Beck Prior to joining PepsiCo, Magazine spent nine years with Procter & Gamble working on numerous brands. He started his career in ad- vertising with Ted Bates among other adver- tising agencies.

Joins from Johnson & Johnson Gelbert, who worked for Pfizer Consumer Healthcare before it was acquired by Johnson & Johnson, has been poached from a similar opment at Procter & Gamble’s Health Care global research and development role at John- division. He holds both a law degree and a doc- Frank son & Johnson Consumer Health Care. torate in chemistry,and has served at the Con- Wartenberg Among his US successes with companies sumer Healthcare Products Association. that have also included Schering-Plough and Led by president and general manager Paul Novartis have been the prescription-to-OTC Sturman, Pfizer’s Consumer Healthcare oper- switches of Claritin, Lamisil, Zantac 150 and ation was established when the company com- Lotrimin Ultra. pleted its US$68 billion (C51 billion) acquisi- In his new role Gelbert would be responsi- tion of Wyeth on 15 October last year. ble,Pfizer said, for “driving and prioritising” Consumer Healthcare forms part of Pfizer’s projects that would bring new products to mar- Diversified businesses division – along with ket. He would also manage the “increasingly the Animal Health, Capsugel and Nutrition units challenging” regulatory environment for OTC – led by Cavan Redmond, former worldwide products, said the company. president of Wyeth Consumer Healthcare (OTC Gelbert began his career in product devel- bulletin,17 April 2009, page 1). OTC OTC

Retail Associations utive Rob Darracott praised Emson’s ability to understand the challenges and needs of the Emson retires as CCA chairman association’s members. These are nine of the UK’s leading pharmacy multiples, represent- igby Emson – who for the past 12 years Chemists – where he spent 32 years – Emson ing nearly 50% of UK pharmacies. D has been chairman of the UK Company joined the CCA board as chairman in 1998, “Since becoming chief executive three years Chemists’Association (CCA) – will step down the same year he became a Boots director. ago, I can vouch for Digby’s determination to from the role as soon as his replacement is ap- Noting Emson’s period as CCA chairman see the CCA evolve and succeed in a rapidly- pointed in the spring. included the organisation’s transition into an changing pharmacy marketplace,”Darracott A former superindendent pharmacist and independently-staffed trade association with commented. director of professional services at Boots the its headquarters in London, CCA chief exec- OTC

22 OTC bulletin 26 February 2010 OTC26-02-10p22-24.qxd 23/2/10 13:12 Page 3

PEOPLE OTC

Manufacturers Industry Associations Lecat moves Seifert plans to step down to Ethypharm from Australian OTC body

rench drug delivery specialist Ethypharm uliet Seifert will retire in August from her Juliet Seifert F has recruited Hugues Lecat as chairman Jposition as executive director of the Aus- and chief executive officer. tralian Self-Medication Industry (ASMI), the Lecat, who was previously chief executive OTC industry association she has led in one officer of the French OTC company Cooper, form or another for the past 21 years. takes over from Olivier Thiberge. She will be replaced by her deputy Deon Before moving to Cooper,Lecat worked Schoombie,who has been the association’s for a number of healthcare companies includ- scientific director since mid-2004. A general ing Medtronic, Rhone-Poulenc Rorer,Aventis medical practitioner,he will take up the post and Sanofi-Aventis. He graduated from the of executive director when Seifert formally École Supérieure de Commerce in Rouen and steps down in six months. has an MBA from INSEAD. The ASMI said Seifert had decided to stand Ethypharm reported turnover of C 147 mil- down for personal reasons, and would spend Deon Schoombie lion in 2008. The company employs around a period of time away from the industry with 850 people worldwide. her immediate family. She joined the Propri- OTC etary Association of Australia – the forerun- ner of ASMI – in 1989. “Juliet’s leadership qualities and her vision IN BRIEF for the industry have transformed the way that ■ NUTRA PHARMA – the company behind we do business and have helped establish the the Cobroxin OTCpain reliever – has hired OTC medicines industry as a key player in the David Isserman as chief marketing officer. healthcare sector,” commented ASMI presid- The US-based company said Isserman would ent Ralf Dahmen. take responsibility for corporate communica- Thanking her members, industry colleagues tions and investor relations, as well as work- and staff for their dedication and support, Sei- ing directly with its licensees to coordinate fert replied that the ASMI had established a tralia, particularly of minor ailments and chronic ongoing marketing and outreach initiatives. “strong industry voice” with links to a wide conditions, and in preventive health, Schoom- Isserman has been a consultant to the comp- range of professional and consumer organisa- bie commented that better access to safe, ef- any for several years. Nutra Pharma said sales tions as well as key government policymaking fective and affordable OTC medicines entail- of Cobroxin, which was launched in the US committees. At the same time, it had signifi- ed “the appropriate down-scheduling of pre- in October,reached US$0.58 million (C 0.43 cantly expanded its range and breadth of ser- scription medicines to non-prescription status”. million) in the fourth quarter of 2009. The vices to members, she added. This would allow consumers to utilise better company noted this had been achieved despite Noting that there was “significant scope” for the pharmacist as the first port of call for some “initial limited retail availability”. encouraging greater consumer self-care in Aus- minor ailments, he said. OTC OTC

Manufacturers SSL International gives Adamson global position

Ian Adamson SL International has promoted Ian Adam- Seton Healthcare in 1991, Adamson has held S son to group commercial director with re- a number of senior sales, marketing and gen- sponsibility for the UK-based company’s world- eral management positions within the group. wide commercial operations. He takes up the Meanwhile, SSL has announced that as part new position on 1 April 2010. of its integration of the eastern European con- Currently SSL’s managing director for Eur- dom distributor Beleggingsmaatschappij Lem- ope and the Americas with responsibility for ore BV (BLBV), Konstantin Kirsenko,gen- group marketing, Adamson was made manag- eral director of BLBV,has been made SSL’s ing director of the company’s European oper- general director for Russia and the Common- ations and given a seat on the board in 2004 wealth of Independent States (CIS). Kirsenko ( OTC bulletin,30 April 2004, page 23). reports to Adamson. Since taking a job with SSL’s forerunner OTC

26 February 2010 OTC bulletin 23 OTC26-02-10p22-24.qxd 24/2/10 06:59 Page 4